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ABSTRACT
The overall objective of this study was to understand
the mechanisms that control antigen processing and binding of
peptides to major histocompatibility complex (MHC) molecules.
Towards this goal I investigated (a) the structural features
of T cell-presented peptides with a focus on the role 
recurrent hydrophobic residues catalysis helix
formation by these peptides and (b) the biochemical events
that determine the fates of the invariant chain molecule (Ii)
in its various post-translational processing pathways.
In the structural studies, I tested the hypothesis that
the recurrence of hydrophobic amino acids in polypeptide 
positions falling in an axial, hydrophobic strip if the
sequence were coiled an a-helix can lead to helical
nucleation on hydrophobic surface. For a series of HPLC-
purified peptides, including some T cell-presented peptides
varying considerably in primary sequence, percentage helicity
in the presenc, of lipid vesicles correlated with strip-of-
viii
helix hydrophobicity index as shown by circular(SOHHI) ,
dichroism (CD) analysis. A prototypic helix peptide PH-1.
(LYQELQKLTQTLK) was designed with a strong axial hydrophobic
strip of 4 leucine residues. PH-1. 0 formed about 38% helical
structure in 10 ro phosphate buffer at pH 7. 0 with di-O-
hexadecyl phosphatidylcholine (DHPC) lipid vesicles, but no
helical detected when the pept ide wasstructure was
phosphate buffer alone.
The helix-forming tendencies of 9 analogs of PH-1. 0 with
one or two amino acid variations from the parent peptide were
examined in the presence of lipid vesicles and the results
showed that (a) decreasing the strip-of-helix hydrophobicity
by substituting even one of the four leucine residues in the
axial hydrophobic strip with a less hydrophobic threonine
residue reduced the helix-forming tendency of a peptide 
the lipid vesicles; the(b) placementpresence
recurrent hydrophobic residues within the axial hydrophobic
strip appeared to be critical for a peptide to be induced to
form an a-helix by a hydrophobic surface; (c) there was an
orientation preference for these peptides to interact with
lipid vesicles and to form helical (d)structure; extra
hydrophobic residues in other positions appeared to compete
with the hydrophobic residues within the axial hydrophobic
strip for interaction with the lipid vesicles and therefore
to decrease the helix-forming tendency of peptides.
i x
For the biochemical studies of the function of Ii,
17-residue peptide, Ii-3 (Ii 148-164), was synthesized. The
CD analysis of Ii-3 showed mainly an a-helical conformation
when the pept ide was examined in the presence of lipid
vesicles. (125I)-labeled Ii-3, after coupling at the N-
terminus with photoacti vatable, heterobifunctional
crosslinker N-hydroxysuccinimidyl-4-azidobenzoate (HSAB), was
able bind to both and P MHCclasschains
molecules, indicating that this region of Ii might cover the
desetope of class II MHC molecules from the time of their
synthesis until their charging with foreign peptides at an
endosomal compartment.
The biosynthesis of a chondroitin sulfate proteoglycan-
form of Ii (CS- Ii) was examined in a class II MHC-negative
(35S) sulfate-labeled microsomal membranecell line P3HR-1.
proteins P 3HR-1 immunoprecipitated with anti-Iiwere
monoclonal antibody and the results of SDS-PAGE analysis
demonstrated that P3HR-1 could process Ii to CS-li in the
absence of class II MHC molecules and the chondroitin sulfate
identity of this molecule was confirmed by chondroitinase-ABC
treatment. We conclude that there might be a class II MHC-
independent pathway to process Ii to a chondroitin sulfate
proteoglycan form as compared to the pathway in which Ii was
associated with class II MHC and later cleaved by proteases
residing in the endosomal compartment.
- -
In an effort to demonstrate in vi tro that the class II
MHC-associated Ii was eventually dissociated from class 
MHC molecules by a proteolytic cleavage process, it was found
that cathepsin B could completely remove Ii without damage to
class II and chains. In order to identify those cleaved
Ii fragments, three polyclonal anti-Ii peptide sera were
produced by immunizing rabbits with keyhole limpet hemocyanin
(KLH) -conjugated Ii peptides. Anti-Ii (146-169) was shown to
able precipitate p18 molecule only cells
expressing Ii. Ant i-I i ( 14 8 -1 64 ) and anti-li(78-92) were
specific for their respective antigenic peptides as tested by
enzyme-linked immunosorbent assay (ELISA).
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CHATER I
INTRODUCTION
A. Specific aims
The overall objective this study has been
understand better the mechanisms antigenthat control
processing and binding to major histocompatibility complex
The following specific questions were asked:molecules.
What structural features determine the selection of T
cell-presented peptides?
What is the role of recurrent hydrophobic residues
in catalysis of helix formation by T cell-presented
peptides?
How does the strength and placement of recurrent
hydrophobic residues in these peptides affect the
coiling of a helical structure?
What are the roles of the invariant chain (Ii) in the
regulation of antigen processing and presentation?
Where is a potential desetope-binding sequence on
the invariant chain and does a peptide from that
sequence bind to class II MHC molecules?
B. Literature Review
T cell antigen
Tnt roduct ion. Although antibodies and some of their
biological effects were described by the late 1800s, the
importance of the thymus and thymus-derived lymphocytes in
antibody production and in the whole immune system was not
generally recognized until the mid 1960s. Lethally
irradiated mice reconstituted with both thymus and bone
marrow cells together with antigen produced a much greater
antibody response than when given either cell source alone
(Claman et al., 1966). Other studies showed that lymphocytes
were divided into two categories: B cells which secreted the
antibodies and T cells which were necessary to "help" B cells
make antibody (Davis et al., 1967; Miller & Mitchell, 1967).
The discovery T-B synergism was cons istent with the
phenomenon known as the carrier effect, e., the antibody
response to a hapten was dependent on the carrier. In order
to obtain a secondary response the hapten must be conjugated
to the same carrier as used for the primary immunization
(Ovary & Benacerraf, 1963). Thus the T cell was shown to be
carrier-specific and the B cell was hapten-specific.
However, T cells and B cells differed fundamentally in
the ways in which they recognized antigens. The B cell
.. 
receptor for antigen (immunoglobulin) bound soluble antigens.
In contrast, the T cell antigen receptor could recognize
antigens only in association with cell surface molecules
encoded in the major histocompatibility complex (MHC) gene
(Kat z et a 1 ., 1 97 3) . In addition, T cells generally did not
recognize native protein antigen, but only antigens that were
processed and subsequently displayed in association with MHC
molecules (Chestnut et al., 1982).
MHC restricted T cell antigen presentation. Class I and
Class II MHC molecules are expressed on the cell surface and,
being part of a ternary complex (T cell receptor, nominal
antigen and MHC molecule), serve as accessory restricting
structures in T cell recognition of protein antigens (Katz et
al., 1973; Zinkernagel, 1976). Class I MHC molecules consist
of a highly polymorphic, integral membrane glycoprotein 
chain) noncovalent ly bound to P2-microglobulin (Orr et al.,
1979) . Class II MHC molecules consist of two noncovalently
bound, highly polymorphic membrane glycoproteins and P
chains) (Humphreys et al., 1976; Kaufmann et al. , 1984) .
Crystallographic analysis of the structure of class I MHC
revealed a groove at the top surface of the molecule formed
by the two amino-terminal domains, a1 and (Bjorkman et
aI., 1987). The three-dimensional structure of the class 
molecule is not available but a similar antigen binding site
. - was modeled by aligning conserved elements between class 
and class II molecules (Brown et al., 1988).
Identifying class and class MHC ant igen-
presenting molecules led originally to a division of T cells
into two classes, cytotoxic T cells (TC) and helper T cells
. (TH) (Cantor et al., 1975; Huber et al., 1978). TC eradicate
intracellular pathogens and tumors by directly lysing cells
and secret ing potentially toxic cytokines such
interferon. The primary funct ion secrete
cytokines that promote the activities of B cells and other T
cells. TH enhance antibody responses and thus help eradicate
extracellular . antigens suscept ible an t ibody-t a rgeted
immune mechanisms. The tissue distribution of MHC molecules
is also consistent with these different functions of TC and
TH. Class I MHC molecules were found on virtually all cell
types. Clas s II molecules were constitutively expressed
largely by cells of the immune lineage that either secreted
cytokines necessary for TH stimulation (such as macrophages)
or required TH cytokines for their own stimulation (B cells) .
Although it was likely that residues from MHC molecules
directly interacted with the cell receptor, the
differential recognition of class I and class II molecules by
cells appeared to stem largely from the interaction of CD8
and CD4 adhesion molecules on the T cell surface with class 
and class II molecules on the antigen presenting cells (APC),
specti vely (Cantor Boyse, 1975; 1989a).Long,
particular interest was Braciale ' s finding of both class I
and class I I- rest ricted, inf luenza- speci fic CTL clones
(Morrison et al., 1986) . Analysis of the differences in
antigen presentation to these two types of CTLs suggested the
close association between the MHC restriction of an antigen-
specific T lymphocyte and the pathway of antigen presentation
to that T lymphocyte. Therefore, the distinction between
class I- and class II-restricted antigen presentation might
be made by the or processing pathway of T cellsource,
antigens: exogenous antigen would be presented by class II
MHC, whereas endogenous antigens would be presented by class
I MHC (Morrison et al., 1986; Germain, 1986).
cell ant igen process ing. Antigen processing
constitutes the structural modification and trafficking of
protein antigens that enable the determinants which will be
recognized by T cells to interact with MHC molecules in the
proper subcellular compartments. The dichotomy of class I
and class II MHC restriction for T cell antigens led to the
hypothesis different cell antigenthat there are two
processing pathways (Long, 1989b).
The requirement for processing of T cell recognized
antigen was first studies on classdiscovered in I I MHC
restricted antigen presentation. Ziegler and Unanue (1981),
the bacterial ant igen Listeria monocytogenes,
discovered major features antigen process ing .two
Firstly, if the antigen presenting cells were fixed after a
processing period had occurred, they were still able to
present antigen to T cells. If the antigen presenting cells
were fixed before the processing period, then no presentation
was observed. Secondly, treatment of the antigen presenting
cell with lysosomotropic agents, such as ammonium chloride or
chloroquine, completely inhibi ted the processing and
presenting capacity of the treated cells. It was concluded
that during processing the antigen must encounter an acidic
intracellular compartment.
Shimonkevitz et al. (1983) further demonstrated that
glutaraldehyde-fixed antigen presenting cells could present a
tryptic digest ova lbumin though they could noteven
present native ovalbumin. Some peptides in the digest were
identified and synthesized, and were able to substitute for
the native antigen in presentation (Shimonkevitz et al. ,
1984) . Using planar membranes containing MHC molecules,
Watts et al. (1984) showed that the minimal requirements for
T cell recognition were antigen-derived peptides and MHC
molecules.
Processing ant igen for clas s MHC- restricted
presentat ion appeared involve proteolysis andalso
recognition of antigen-derived peptides bound to class I MHC
lIo1.ecules. The reports of class I MHC-restricted T cell
'recogniti of the expressed products of truncated viral
enes (Gooding & O' Connell, 1983; Townsend et al., 1985) and
sensitizatio of target cells by synthetic oligopeptides
corresponding to specific portions of a viral polypept ide
J(Townsend et al., 1986) led to the hypothesis that, like
lass II MHC-restricted T cells, T cells restricted by class
MHC products also recognized proces sed" and possibly
degraded forms of protein antigens (Townsend et al., 1985,
986) . However, processing class MHC-restricted
antigens was less sensitive to chloroquine and was usually
not secondary to endocytosis of antigen (Morrison et al.,
1986) .
Therefore, it appeared that there might be two distinct
pathways to process T cell antigens. The two pathways
differed in three major features: sensitivity to agents such
as lysosomotropic amines that raise endosomal pH and/ or
interfere with endosomal trafficking; the subcellular portal
:for entry of antigen into the pathway; and the MHC molecules
used to present processed antigens (Yewdell & Bennink, 1990).
The endosomal pathway was sensitive to lysosomotropic
amines. Endosomal processing of many antigens was also
ert$itive to specific inhibitors of endosomal and lysosomal
proteases (Takahashi et al., 1989). Determinants produced by
this pathway exclusively associated with class II molecules,
which explains why soluble antigens generally elicit TH and
not TC responses. Antigens might enter the endosomal pathway
by either fluid-phase pinocytosis or absorptive endocytosis,
following the interaction of antigen with receptors on the
surface of the antigen presenting cell. The considerable
increase in efficiency provided by absorptive endocytosis had
important consequence vivo, where antigens were
commonly presented to TH by B cells expressing antibodies
specific for the antigen. This enabled provide
specific help to B cell clones of the appropriate specificity
(Taussig, 1974).
The cytosolic pathway was resistant to lysosomotropic
amines and was accessed through the cytosol, either by the
synthesis proteins the penetration pIa s 
endosomal membranes by extracellular proteins. Penetration
might occur naturally through the fusion of virus and cell
membranes (Yewdell et al., 1988), or artificially by osmotic
lysis of antigen-containing endosomes (Moore et al., 1988) .
Determinants produced by the cytosolic processing pathway
typically associated with class I MHC molecules.
There were several examples of class II MHC-restricted
presentation of endogenously synthesized antigens (Jin et
al., 1988; Weiss & Bogen, 1989; Eisenlohr & Hackett, 1989),
but they all involved transmembrane proteins expressed at the
surface of target cells and thus it was possible that these
,--- "
antigens were targeted into endosomes either during transport
to the cell surface or by recycling from the cell surface
(Long, 1989).
It is not clear what molecular mechanism determines
hether a T cell antigen is presented by class I or class II
MHC molecules, but it was suggested that the invariant chain
might play a role in such a different restriction patterns
(Long, 1989; also see detailed review about the function 
invariant chain on page 24) .
Biochemical studies of T cell presented peptides. The
first direct biochemical evidence specific T cell
antigen/MHC complex came from equilibrium dialysis studies in
which an I-A restricted immunogenic peptide derived from hen
egg lysozyme (HEL 46-61) was bound to affinity-purified I-A
but not I-Ad molecules in a non-ionic detergent solution
(Babbitt et al., 1985). The binding of this peptide to I-A
was specific and had a dissociation constant of 2-4 
This finding was subsequently confirmed in other similar
studies (BuuS et al. 198 6a, 1 98 6b , 1987; Guillet et al.
1987) . Buus et al. reported that binding of 12 immunogenic
peptides to purified class II MHC molecules correlated well
with the known MHC-restrictions of these T cell antigens.
The capacity of a peptide to inhibit the binding of 
antigen to purified class II MHC also correlated with the
. n -- capacity of the peptide inhibit presentation of the
antigen by APC (Buus et al. 1987). The thermodynamics of
peptide-MHC
interact ion
interactions showed a relatively low affinity
(KD of 5-50 M), a rate of association (ka) of
approximately 1 M-1 -1 and a rate of dissociation
approximately 7 x 10-5 s-l (Buus et al. 1986b).
(kd) of
These studies indicated that synthetic peptides from
'unrelated protein antigens manifest ing the same MHC
:restriction could compete with each other for MHC binding.
The interaction of I-Ak with HEL (46-61) was competed not only
with various HEL(46-61) derivatives but also with unrelated
peptides which included HEL (34-45) and peptides derived from
other unrelated proteins presented I-A such
ribonuclease A (Allen et al., 1987b). It was concluded that
there might be only a single binding site on any given class
II MHC molecule, but this site could probably recognize
broadly defined motifs (BuuS et al., 1987, Sette et al.,
1987) because attempts to define a primary binding sequence
on imiunogenic peptides have not been very successful. This
also suggested that in binding to MHC molecules, a T cell
antigen might have created a novel and stable conformation.
Such a novel conformation could be generated by a T cell-
presented peptide along with portions of the MHC molecule,
which would then serve as the substrate for recognition by
the T cell receptor (Werdelin et al., 1988).
pt rnct ural features of T cell presented peptides . In
contrast to antibodies, the antigenic structures seen by T
cell receptors did not depend on an intact configuration of
the immunizing protein, but could be defined sufficiently by
primary amino acid sequence, as suggested over 20 years ago
( Ge 11 & Benacerraf, 1959; Sela, 1969) . The ability 
antigen presenting cells present either proteolytic
digests and cyanogen bromide fragments of antigenic proteins
or synthetic peptides to T cells supported this old theory
(Shimonkevitz et al. 1983; Livingstone & Fathman, 1987).
Because (a) fragments of the antigenic protein can
stimulate a T cell response that is as great as the response
to native antigen, and (b) peptide technology has advanced, a
new strategy for defining T cell epitopes has been developed.
Now one can synthesize sets of overlapping, nested"
peptides, serially removing one amino acid from either end
and testing for their ability to stimulate specific T cell
clones or hybridomas. This strategy was applied to fine
specificity mapping of cell epitopes number of
globular protein antigens (Watts et al. 1985; Allen et al.
1985; Schwartz et al. 1985; Berkower et al. 1986). Some T
cell epitopes could be as short as 7 amino acid residues
(Livingstone & Fathman, 1987).
Nevertheless, accurate definition of a T cell epitope
could be rather more complicated. The residues outside the
minimal T cell epitope sequence might not be essential for
stimulation whereas they could still play an important role
,in determining the antigenic potency of the peptides. One
possibility was that these residues stabilized a particular
secondary structure for peptides or contributed directly to
the affinity of the interaction among nominal antigen, class
II MHC and T cell receptor.
Since a large number of substituted analogs of antigenic
peptides appeared to bind to class II MHC molecules and each
to stimulate antigen specific T cell response (Sette et al.,
1987), the requirements for peptide-MHC interaction might be
highly permissive. This finding was consistent with the
determinant se lect ion hypothesis which required that
relati vely few MHC molecules had the capacity to bind a large
universe of foreign antigens. The critical question was what
were the structural requirements for these antigenic peptides
to be selected during antigen processing and presentation?
The search for structural features intrinsic to the T
cell- recognized determinant s which contributed
immunodominance has been aided by the ability to focus on
just the primary and secondary levels of peptide structure.
Since T its processing bysaw antigen aftercells only
antigen which involvedcells,presenting process
oteolysis or at least unfolding of the native structure
(unanue, 1984 ; Allen, 1987a) , appear that thewould
native, tertiary structure of a protein ant igen did not
contribute much to the final of the antigenicstructure
determinants which were seen by T cells. Thus, in contrast
antibodies, T cells did not appear to recognize assembled
topographic (or discontinuous) sites.
The first attempt to find a structural feature of an
immunodominant T cell site was a series studies of a
single such site the carboxyl terminus pigeon
cytochrome c (P incus et al., 1983; Schwartz et al., 1985 ;
Carbone et a 1 . , 1987; Fox et al., 1988;). It was observed
that the potency of a series of peptides of different lengths
and variant sequences from this region for stimulation of T
cell clones and hybridomas correlated with their predicted
and measured ability to fold as a-helices.
These and other similar observations (Berkower et al.,
1986), combined with theoretical considerations, led to the
hypothesis that T cell sites tended to be amphipathic 
elices, meaning a-helices that have hydrophilic amino acids
on one face and hydrophobic amino acids on the opposite face
(DeLisi & Berzofsky, 1985). Later, Spouge et al. (1987) made
a statistical analysis of a database of 23 T cell antigenic
sites in 12 proteins and concluded that as a group these 
sites (a) tended to be amphipathic a-helices; (b) consisted
6f residues that had a propensity to form helices and tended
not to form random coils, and (c) tended to have lysine at or
near the carboxyl terminus.
Based on this amphipathic helix hypothesis, Margalit et
al. (1987) developed an algorithm to predict the location of
potential T cell antigenic sites. It was reported that the
computer program AMP HI, based this algori thm, could
predict 18 of 23 immunodominant helper T cell sites noted
above.
Another approach to identify T cell sites was taken by
Rothbard and Taylor (1988) who found a sequence pattern
common to the primary sequences of known T cell antigenic
sites and formulated a predictive template based on this
pattern. They defined mot i f either four or five
consecutive residues. The four- residue motif was the
pattern: charged or glycine, hydrophobic, hydrophobic, polar
or glycine; and the five-residue motif was the pattern:
charged or glycine, hydrophobic, hydrophobic, hydrophobic or
roline, polar or glycine. In their motif, the amino acids
threonine and tyrosine were treated as being both hydrophobic
and polar due to the physical properties of their side
chains. helper andwas found that known
cytotoxic T contained one of theircell antigenic sites
motifs and that the patterns were useful in identifying eight
new helper and three new cytotoxic T cell epitopes in four
a1fferent proteins. This method, however, could not give the
ranking order for T cell epitopes.
Dr. Humphreys and his proposed anothercolleagues
approach to identify sequences closely related to T cell
epitopes (Stille et al., 1987; Reyes et al., 1988) . They
developed a different helix hypothesis through the analysis
of the invariant chain, a glycoprotein which associated with
the class II MHC molecule at the time of MHC synthesis and
was dissociated from class I I MHC later probably in an
endosomal compartment (Elliott et al. 1987a, 1987b) . They
computed only the hydrophobicity down one side of the helix
as a measure of its potential antigenicity by using strip-of-
helix hydrophobicity index (SOHHI), the mean hydrophobicity
(in the Kyte-Doolittle scale) of sets of amino acids in
longitudinal axial strips down one side of helices for 3-6
turns, at positions, n, n+4, n+7, n+11, n+14, and n+18. Such
residues would form a strip along one face if the segment
from n n+18 folded into a-helix, wasandwere
hypothesized residues sufficientlythesethat were
hydrophobic, the segment would be selected as a T cell-
presented epitope. A computer algorithm, the strip-of-helix
hydrophObicity algorithm (SOHHA) was produced based on this
hypothesis and took into account the presence of proline and
the presence of carboxy 1 terminus of alysine near the
segment. This algorithm could be used to identify both class
MHC-restricted T cell epitopes with ranking
order for these sites within an antigenic protein.
The sites predicted on the basis of any of the above
hree methods did not correspond in every case while there
:Was considerable overlap. they all have somemay
structural basis but at the same time none of the three
methods could predict all the T cell sites. Therefore the
real challenge was to understand why T cell antigens need to
have certain proposed structural features.
noteworthy that whi Ie differing widelywas
unction, the antigenic determinants recognized by TC and TH
/were chemically and structurally similar al. ,(Reyes et
1988) . Most determinants recognized by T cell receptors
Gould be substituted by synthetic peptides corresponding to
. .
'Gontinuous intact proteins. Al thoughthesequences
certain features of peptide sequences favor binding to MHC
molecules in general, specific class I and class IIor a
llele in part icular, there are no obvious properties that
1!avor binding to class I versus class II molecules. In fact,
many synthetic peptide antigens can bind multiple class I and
ilas Hickling et al.II alleles (Perkins et al. , 1989;
cell presented peptides.Biophysical studies
::,
:Generally, there were very limited studies using biophysical
;;.
Ft001S to charavterize the secondary 
structures of T cell-
peptides. By using synthetic peptide analogs of
the carboxy-terminal sequence of moth cytochrome c, Schwartz
et al. (1985) tested the hypothesis that increased antigenic
potency could be contributed to the stabilization of the
secondary structure molecule a-helicalthe
configuration. They found that the minimum-sized peptide
capable stimulating full cell was mothresponse
cytochrome c fragment 97-103. Addition of more amino acids
at the amino terminal end increased the antigenic potency in
uneven increments, with a large contribution being made at
residue 95 which can only accept hydrophobic or non-charged
residues. of helix largerformation ofThe degree the
analogs was assessed by circular dichroism (CD) measurements.
A good correlation was found between antigenic potency and
percentage of a-helici ty for peptides of increasing chain
length. suggested thatThese results secondary structure
might play an important role in determining the potency of
antigenic determinant s invol ved activationthe
lymphocytes.
Further studies this system1987)(Carbone et al.
showed that the presence of an amino-terminal leader sequence
generated helically (a-constrained amino acids
arilinoisobutyric acid and alanine) had a general effect on
enhancement of T cell recognition and a strong preference for
t;he helical conformation in nonpolar solvents as shown by
CD measurement s .
Lark et al. (1989) reported the biophysical properties
of a series of peptides from sperm whale myoglobin (SWM)
which were already characterized with respect to activation
of T cell clones from mice immunized against the whole
protei Their CD studies suggested that peptides 132-146
and 102-118, corresponding to immunodominant T cell antigenic
sites from SWM, tended to fold as amphipathic a-helices in
helix-promoting environments, such as trifluoroethanol (TFE)
or sodium dodecylsulfate micelles (SDS) . Control peptides
93-102 and 115-130 did not have T cell stimulatory activity
and took up little ordered structure by comparison.
Collawn et al. (1989) analyzed the peptides I physical
properties that influence the T cell response. Although the
B10. A T cell proliferative response was directed to pigeon
cytochrome c 95-104, residues added to the amino-terminal
side of this determinant could influence antigen-specific T
cell A series of analogs were synthesizedrecognition.
containing determinant, residues 95-104, plusthe core
various seven- res idue, non-native, whichleader sequences
were designed, in comparison with the native determinant, to
make the whole peptide more or less helical, amphipathic, or
lipid binding. The structure of each analog in aqueous, non-
polar (TFE) or lipid environments was determined by CD.
additio , the ability of each analog to bind to phospholipid
membranes and to stimulate two different pigeon cytochrome c
specific T cell hybridomas, 2B4 and 22. D11, was investigated.
It was found that in a group of 15 analog peptides, only two
peptides with the potential amphipathic, leader sequences
could coil as an a-helix in lipid vesicles and they bound
membranes better than other peptides. Therefore, non-
determinant leader might stabilize core.thesequence
determinant helical conformation against membrane
structure before the peptide could be further charged to the
desetope of MHC molecules.
The data were consistent with the possibility that even
T cell-presented . sequences which were not helical in the
native protein could still fold as helices when freed of the
constraints of the native protein, during antigen processing
and binding to MHC molecules. One such example was hen egg-
white lysozyme 52-61 which in the native structure of(HEL)
HEL was located in a series of ~-pleated sheets. In solution
HEL (52-61) had no detectable ordered conformation, but the
results of peptide binding and T cell stimulation suggested
that HEL (52-61) could fold as an a-helix structure during
the process of binding with class II MHC molecules (Allen et
aI., 1987c).
IJ.
The invariant chain (Ii)
Structure. Humphreys et al. (1976) found a 31, 000
dalton, third chain which was associated with human class 
MHC and ~ chains and was labeled with (35S)methionine but
(not radioiodinated by the lactoperoxidase method. Jones et
v'al. (1978) found the comparable chain non-in the mouse
covalently associated with class II MHC molecules. They
esignated this protein invariant chain because of its lack
of electrophoretic polymorphism. The existence of Ii was
again confirmed in the human system McDevitt,(Charron 
1979) . This molecule has been called various names, the
nvariant cha in, In chain, Ii, 1 chain, and CD 74 (Dorken et
al. 1989).
After cloning of the complementary DNA for Ii(cDNA)
(Claesson et al., 1983; Strubin et al., 1984; Singer et al.,
1984), Ii was found to be encoded by a single copy gene which
was located on human chromosome 5 and murine chromosome 18
whereas the MHC molecules were encoded from human chromosome
6 and murine chromosome 17 (Yamamoto et al., 1984; Cleasson-
Welsh et al., 1984).
The Ii gene encoded a type-II glycoprotein with its N-
minus side the membrane.cytoplasmicthe
proteins experienced a broad post-translational processing.
'There were two N-linked glycosylation sites at positions
Asn1l4 and AsniA20 while two O-linked oligosaccharide units
were found at unknown locations (Machamer & Cresswell, 1982;
Claesson-Welsh al. , 1986) . Both the N-linked
carbohydrates were processed to a complex form with sialic
acid on their side chains (Rudd et al., 1985). Ii could be
fatty acylated by palmitic acid at Cys28 adjacent to the
cytoplasmic part of the membrane (Koch & Hammerling, 1985 ;
Koch, 1988). Spiro and Quaranta (1989b) demonstrated that Ii
could phosphorylated one serine res idue the
cytoplasmic tail , possibly at positions 9, 26 or 29 in the N-
terminal portion of Ii.
Ii was also the core protein of the class MHC-
associated chondroitin sulfate proteoglycan molecules (CS-
Ii). Ii was degraded by proteolytic cleavages with multiple
proteases more than one degradative pathways. (The
detailed literature on these two types of Ii processing will
be reviewed on page 26 and 29.
The single gene for Ii had multiple protein products,
utilizing alternate initiation sites for translation and
alternative RNA splicing. Alternate use of two in-phase AUGs
resulted in two different forms of the Ii protein, p31 and
p35 (or 12/13) (Strubin et al. 1986; O' Sullivan et al., 1987).
The p35 form had 16 additional amino acids from a sequence
encoded between the two AUGs. If an additional cysteine-rich
exon (exon 6b) was included in the final transcript, the Ii
gene would produce the species called p41 (Strubin et al.,
6; O' Sullivan et al., 1987; Koch et al., 1987) rather than
the regular p31 form.
Ii was expressed in all cell types expressing class 
MHC molecules (Hammerling & Moreno, 1990 ) and induct ion 
class II a and ~ lymphokines, IFN-chains was
accompanied by induct ion al. , 1986) .(Mombeurg et
While class II MHC molecules were clearly expressed on the
cell surface, the answer for whether Ii was also expressed on
the cell surface was not very clear for long time. Recent
studies (Wraight et al. 1990) using several new monoclonal
antibodies which recognized an extracytoplasmic determinant
reinforced previous suggest ions could bethat
expressed on the cell surface (Koch et al. 1982). The cell
surface expression of Ii was much weaker than class II MHC as
shown by flow cytometry and most Ii on the cell surface did
not appear to be associated with class II MHC molecules.
Class II MHC molecules (both and p chains) and Ii
associa ted after their biosynthe s i thevery soon
endoplasmic reticulum (ER) (Kvist et al. 1982). This complex
was transported through the Golgi apparatus into an endosomal
compartment (Machamer & Cresswell, 1982; Claesson & Peterson,
1983 ) class II molecules presumably met endocytosedwhere
antigens At the same time (Hammerling & Moreno, 1990) .
dissociated result ofI I MHC moleculesfrom class
cleavage into various small molecular weight fragments (Blum
Cresswell, 1988; al. , 1989; al. ,ReyesNguyen
unpublished observation). Class II MHC molecules complexed
with the exogenously derived peptides then moved to the cell
surface. The coexpression and physical association of class
II MHC molecules with Ii led to the assumption that the
function of Ii must be tightly connected with the function of
class II MHC molecules (Hammerling & Moreno, 1990).
Hypothesized Funct ions of Ii It is still unclear
whether funct ion antigen-processing andhas any
presentation. Stockinger al. (1989) thatshowed
cotransfection of I-Ed and Ii genes to L cells led to more
efficient proces ing and presentation of the C5 antigen to
C5-specif ic clone T58C1 with cellscomparedcell
transfected with only I-Ed genes. However, other studies
(Peterson & Miller, 1990), using L cells, COS cells, rat-2
and CHO transfected with I-Ad or I-Ek as antigencells
presenting cells and ovalbumin, insulin and cytochrome C as
antigens, showed that the presence of Ii did not improve
processing presentation respect i ve celltheand
hybridomas. Different results were reported even in the same
type of antigen presenting cells. Hammerling & Moreno (1990)
reported that the processing and presentation of hen-egg
lysozyme (HEL) by a set of I-Ak- and Ii-transfected, rat-2
fibroblasts was improved when stimulation of a panel of T
hybridomas specific for different HEL determinants was
used as the readout system. However, with the same set of
transfectants, no influence of Ii on the presentation of
another antigen, RNase, was found. It appeared that for some
. but not all antigens, Ii-positive cells might be more potent
antigen presenting cells than Ii-negative ones.
Currently, there are several hypotheses to explain how
the invariant chain might exert its function in the cases
where antigen presentation was clearly improved.
First, Ii might block the peptide binding groove early
in the biosynthetic pathway, protecting class I I MHC from
association with endogenous peptides that could compete with
foreign antigens (Elliott et al. , 1987). Preventing such
binding until the class II MHC molecules entered an endosomal
compartment could maintain the functional dichotomy between
class I and class II MHC molecules. Roche & Cresswell (1990)
reported that the isolated HLA-DR5 a/~ dimers effectively
bound radiolabelled influenza haemaglutinin peptides(HA)
while Ii-associated forms of DR5 did not.
alternative this blocking hypothesis, the
invariant chain was suggested to keep class II MHC molecules
in a conformational state which bound peptides lowwith
affinity (Hammer ling & Moreno, The removal of Ii in1990) .
endosomes would allow the class II MHC molecules to snap into
another conformation with high affinity for certain antigenic
,peptides. One evidence for this theory was the observed
conformational changes of class II MHC molecules. Peterson
and Miller (1990) reported that certain antibody determinants
I-A cells were stronglytransfectedmolecules
'influenced by the presence or absence of Ii in these cells.
The third hypothesis suggested that Ii might play a role
,in sort ing clas s molecules into endosomes whe rethe
exogenous antigen was met (Hammerling & Moreno, 1990). There
was little evidence yet for this hypothesis. An earlier
hypothesis similar to " sorting hypothesis " suggested that Ii,
as a transporting vesicle, required for cell surfacewas
expression class MHC molecules. thisHoweve r ,
transport hypothesis was later dismissed because transfection
studies showed that class II MHC could be fully expressed on
the cell surface in the absence of Ii molecules (Miller &
Germain, 1986; Sekaly et al., 1986).
The various hypotheses about the function of Ii do not
exclude each other and they are testable. Detailed studies
of these hypotheses would offer a molecular mechanism to
explain ant igenregulatory effectwhy has some
presentation systems.
another component in the murine classIn 1983,
II MHC/li complex was reported (Sant et al., 1983; 1984). It
was a sulfate-bearing molecule with considerable molecular
weight heterogeneity (46-69 kD by SDS-PAGE analysis). This
component was immunoprecipitated with monoclonal antibodies
specifi for I-A, I-E and Ii glycoproteins but it was not
detected in control precipitates employing normal mouse serum
or an irrelevant monoclonal antibody, nor in association with
class I MHC molecules. This component was characterized to
be a chondroitin sulfate proteoglycan in nature. The core
protein of this murine class II MHC-associated proteoglycan
was found to be the mur ine invar iant chain (Sant et al.,
1985a), and thus established the proteoglycan to be 
alternatively processed form 0 invariant chain (CS-li)
associated with class molecules. This result was
confirmed by the finding that the human invariant chain and
some of its related components were the core protein (s) of
the human class II MHC-associated proteoglycan (Giacoletto et
al., 1986). The site of glycosaminoglycan addition to CS-li
Ser201 in the murine Ii protein sequence, as
shown by site-directed mutagenesis (Miller et al., 1988) .
Treatment of antigen presenting cells with a selective
inhibitor of proteoglycan synthes is, nitro-phenyl P-D-
(xyloside) , prevented the addi t ion
lycosaminoglycan ( GAG) Ii and also depressed antigen
responsive helper cells (Sivak al.,
This phenomenon was reproduced with class MHC-
virus specific, cytotoxic lymphocyte line
(Rosamond et al., 1987) . At xyloside concentrations of 2.
and 5. 0 ro, CS-li synthesis was completely inhibited with
marginal inhibition of protein synthesis. The inhibitory
effect on CS-li synthesis was completely reversible. The
number of class II MHC molecules on the cell surface was not
affected by xyloside, but sensitization of target cells was
markedly inhibited when target cells were exposed to virus in
the presence of xyloside. It was not known why xyloside'
inhibi ted antigen processing and presentation events
associated with class II MHC molecules.
Understanding the function of CS-li was complicated by
insufficient information about the biosynthesis of CS-li and
the association between CS-li and class II MHC molecules.
Sant et al. (1985b) found that (35S) sulfate-labeled CS-li
molecules were detected in association with class II MHC
immediately after a 15-min pulse, but were barely detectable
after a 30-rnin chase, and were completely undetectable after
a 60-min chase. Similarly, newly synthesized (3H) leucine-
labeled class II MHC molecules associated with the CS-li were
detectable immediately after a 20-min pulse, but could not be
detected in association with the CS-li after a 300-min chase.
Virtually no CS-li was found free in the cells or was
secreted into the media, but at any time point, only 2-5% of
class II MHC molecules were associated with the CS-li. These
findings led to the suggestion that class II MHC-associated
'1'
converted to the proteoglycan during transport.was
However, these results could not distinguish whether some or
all of the class II MHC molecules associated transiently with
the CS- Ii, only small fraction clas s MHC
associated permanent ly with the CS-li short-lived
complex.
Such biosynthetic intermediates of class II MHC/li/CS-li
complex were isolated from detergent extracts of human B
lymphoblastoid cell lines (B-LCL) by Kelner and Cresswell
(1986) who found that the complex contained the p chains of
class MHC and 1: 1: 1 ratio plus a proteoglycan
molecule wi th Stokes mean radi us of a 180 kD globular
protein. Treatment of B-LCL with 10 ro monensin for 24 hr
cou Id enrich the population such complexes be fore
purification. However, both this study and the studies of
Sant et al. (1985b) could not show whether class II MHC was
necessary for the biosynthesis of CS-li.
Proteolyt ic Cleavages of Ii shown that thereIt was
were at least two degradative pathways for Ii molecules which
were associated with class II MHC (Thomas et al., 1988; Blum
& Cresswell, 1988; Nguyen et al., 1989).
The cleavage of Ii to p25 occurred intracellularly and
was shown by both anti-Ii and anti-class II MHC antibodies
(Koch Hammvling, 1982 ; al. , 1988) . TheThoma s
relationship of p25 to Ii was suggested by Giacoletto et al.
(1986) who demonstrated that Ii and p25 derived from SDS
electrophoretic immunoprecipi tates similargels had
tryptic peptide maps.
p25 was shown to be an exomembranal, C-terminal fragment
of Ii because (a) reprecipitation of denatured, anti-Ii mA-
immunopurified Ii-containing complexes by two rabbit antisera
to C-terminal Ii peptides could immunoprecipitate p25, while
antiserum N-terminal peptide failed
precipitate p25 ; VIC-Y1, anti-Ii mAb,(b)
immunoprecipi ta ted (35 S) methionine-labeled notp25 but
(35S) cysteine-labeled p25, consistent with the loss of a
portion of Ii containing the only cysteine in CysIi,
(Thomas et al., 1988).
Cleavage of Ii to p25 appeared to occur in an ER or cis-
Golgi compartment (Thomas et al., 1990) . Since p25 was
completely sensitive to treatments with endoglycosidases F
and H, its carbohydrate side chains might be derived from a
high mannose form of I i rather than from the complex sugar
forms. The maximal labeling of p25 was seen at 20-40 min
chase time in a pulse-chase experiment using (35S) methionine-
labe led, lymphocytes. Theact i vatedpolyclonally
appearance of p25 in an ER or cis-Golgi compartment suggested
that there could exist an early Ii degradative pathway to
destroy incomplete complexes of class II MHC proteins and
molecules or that Ii could retard the class II MHC
IJo 1 e cu 1 e s to be further transported to 
meet the foreign
: "' ':.- ".. ..".
:i:!~WF(peptides at an endosomal compartment.
The second, late, degradative pathway was
inhibitor-sensitive pathway. Incubation of cells
;w,ith leupeptin or antipain, but not wi th chymostat in 
revealed two proteolytic intermediates p21 and
hr after synthesis of the class II MHC/Ii complex
Cres swe ll, 1988; Nguyen al. , 1989) . These
,:eupeptin- induced proteins were named LIP (Blum & Cresswell,
They were determined to be derived from the 
region of Ii by peptide mapping and precipitation
with various anti-Ii peptide antisera specific for either C-
terminal or N-terminal portion of Ii protein.
Monensin, which blocked transport of class II complexes
the medial-Golgi compartment, prevented the generation
molecules. Chloroquine also blocked the leupeptin-
appearance LIP. Treatment LIP with
F and H showed that both of its N-linked
joligosaccharides were in the complex form, indicating that
proteolysis of Ii to generate LIP occurred in a late-Golgi or
post-Golgi compartment (Blum & Cresswell, 1988).
One interpretation for this result was that
iss,ociation from class MHC required least two
rpteolytic steps. Cleavage of the processed by a
leupeptin-insensiti protease generated LIP which remained
associated with the class II MHC. A second cleavage with a
fragments that noleupept in - sen s it i protease generated
molecules. Sincelonger as sociated with class
leupept in antipain generatedand
MHC
LIP and both them
inhibited the intracellular protease cathepsin B, cathepsin B
was suggested to be the enzyme responsible for the second
proteolytic step. More work is needed to identify the enzyme
critical to completelyat the first step which might be
remove Ii from class II MHC and open the desetope for foreign
pept ide charging.
CHAPTER I I
MATERIALS AND METHODS
Cells
The EBV-transformed lymphoblastoid cell lines Jesthom
(HLA-A2, B27, DR1, DP4) and Vavy (HLA-A1, B8, DR3, DP1, DQ2)
were provided by Dr. Charles Carpenter (Brigham and Woman
Hospital, Boston).
Raji was a Burkitt' lymphoma cell line (Pul vertaft,
1965) . Jijoye and its mutant, daughter cell line, P 3 HR-1
were established from a Burkitt' s lymphoma patient (Hinuma,
1967) . CEM was a human acute lymphoblastic leukemia cell
line (Foley et al., 1965).
Cells were grown in RPMI 1640 medium supplemented with
10% fetal calf serum, 100 units/ml penicillin, 100 units/ml
streptomycin, and 2 ro glutamine. Cultures were maintained
at 37 C in a 5% C02 humidified air atmosphere. Cultures were
used in logarithmic growth phase.
Antibodies
The anti-human monoclonal ant ibody (mAb) VIC-Y1
(Quaranta al., 1984) was the gift Dr. Knapp
(University Vienna, Austria) . The anti-chondroitin
sulfate monoclonal antibody 7D4 was the gift of Dr. Bruce
Caterson (University of North Carolina at Chapel Hill) .
The hybridoma cells which produce anti-HLA-DR, DP mA
IVA-12 (Capra & Giles, 1985) and anti-human Ia mA L243
(LampSOn, 1980 ) were purchased from American Type Culture
Collection (ATCC). Ascites fluids were aspirated from mice
primed with pristane and injected with these hybridoma cells.
The antibody titers were tested before use.
Rabbit anti-Ii (183-193) serum E1 was generated in the
Lab (Thomas et al., 1988).
Metabolic Radiolabeling
Standard procedures with slight modification were used
(Spiro et al., 1985). Cells in logarithmic growth phase with
over 95% viability were washed once in RPMI 1640 medium
supplemented with 10% FCS. For (35 S) methionine labe 1 ing 
1X108 cells were incubated for 3 hr in 5 ml methionine-free
RPMI 1640 (GIBCO) ith O. 5 -1 . 0 mC i (3 5S) methionine (NEN,
Cat. No. : NEG-OO 9L) For (35S) sulfate labeling, 2X107 cells
were labeled for 6 hr in 5 ml Earle s balanced salt solution,
with MgC12 substituted for MgS04, supplemented with amino
acids and vitamins from an RPMI 1640 selectamine kit (GIBCO)
and 2 mCi (35S)sulfate (NEN, Cat. No. : NEX-041). Cells were
labeled at 37 C in a humidified atmosphere containing 5% C02.
Microsomal Membrane Preparation
For most of the experiments, a two-step lysing procedure
was used. Cells were first pelleted and lysed in 10 ro Tris-
,,'
pH 8. 1 . After removal of nuclear debris by
centrifugati the decanted to a 30 mlsupernatant was
polycarbonate ultracentrifuge tube. Membrane pellets were
isolated by centrifugation above supernatantof the
100, 000 for Membrane proteins thenhr. were
solubilized in PBS containing 1% Triton X-100. Insoluble
material was removed by centrifugation at 100, 000 x g for 
hr. Both lysing buffers contained 2 ro phenylmethylsulfonyl
fluoride (PMSF) and 10 ro N-ethylmaleimide (NEM). For some
experiments, radiolabeled cells were directly solubilized in
PBS at pH 7. 2 containing 1% Triton X-100, 2 ro PMSF and 10 ro
NEM. The supernatant was collected after the cell extracts
were centrifuged at 100, 000 X g for 1 hr. All the steps were
done at 4
Immunoprecipitation
The detergent-solubilized cell lysate was incubated at
C for 2 hours with 50 l of normal rabbit or normal mouse
serum (NRS or NMS) Proteins bound nonspecifically by NRS or
NMS were then cleared by incubating above mixture with the
pellet from 800 l of 10% formalin-fixed Cowan I strain 
aureus suspension which had been washed and pelleted three
times in a 0. 05% (w/v) Triton X-100 buffer (150 ro NaCl, 5 ro
EDTA, 50 ro Tris, 0. 02% sodium azide, pH 7. 4) .
o Immunoadsorbents were prepared separately by incubating
specific antibodies with 100 J.l of preswollen protein A-
Sepharose (Sigma) for 2 hr at 4 After washing twice with
Triton X-100 buffer, the immunoadsorbent s were
.fncubated with precleared, solubilized lysate overnight at
On the following day, the complexes were washed five
tdmes with 0. 05% Triton buffer, and the immunoprecipitated
material was eluted in SDS sample buffer.
Electrophoresis
\ '
The one-dimensional (l-D) sodi um dodecyl sulfate
polyacry lamide gel electrophoresis (SDS-PAGE) system of
Laemml i (1970) was used. 10% or 14 % polyacrylamide slab
gel was made with a Tris buffer (pH 8. 8) containing 0. 1% SDS.
The Tris-HCl buffer (pH 6. 8) with 0. 1% SDS was used in 
polyacrylamide stacking gel. The gels were run
electrophoretically at 20 mA per gel until the dye front
reached the lower edge of the gel. Gels were either directly
stained or fixed for 30-60 min in 15% acetic acid followed by
60 min incubation in autofluor prior to autoradiography.
Peptides
MT11-A was the gift of Dr. Ciardelli (Dartmouth
Medical School, Hanover). The other pept ides in this study
were synthesized by the University of Massachusetts Medical
Center peptide nthesis facility and I did the desalting and
ication work. The peptides were desalted by Sep-Pak C18
cartridges (Waters, Milford, MA) and were purified by a
preparative C18 column (Vydak, Milford, MA) in a reverse
phase HPLC system (Waters) with a gradient of o to 75%
Acetonitrile in 0. 1% Trifluoroacetic acid. The compositions
of most peptides were confirmed by amino acid analysis (AA)
using a WISP HPLC system (Waters) with a standard PICO-TAG
procedure as suggested by manufacturer s manual. Ii-2 and
Ii-3 peptides were sequenced Dr. John Mole lab
(University of Massachusetts Medical School) .
Circular Dichroism Studies
Peptides were analyzed in 0. 01 M sodium phosphate buffer
in that buffer with 45% TFE, or in that buffer
di-O-hexadecyl D, L-a-phospha tidy lcho line (DHPC)
vesicles. The samples with the vesicles were prepared for CD
measurements by the method of Vogel (1987). About 300 Ilg of
was dissolved in 300 III of HPLC-grade methanol. DHPC
( 10 mg) (Sigma, Cat No. P-3777) was dissolved in 1. 0 ml of
HPLC-grade methanol. The lipid solution was divided into two
equal parts, to one of which was added 150 III (=150 Ilg) of
the peptide solution. Both samples were evaporated in vacuo
in a speed evaporating centrifuge for 1 hr without heating,
followed by 2 hr of high vacuum in a desiccator. Each sample
was added with 500 III distilled water and warmed at 37 C for
3 hr with occasional vortexing. The samples were lyophilized
overnight. Distilled water was added to each(375 Ill)
sample. After vortexing briefly, each sample was sonicated
for about 5 min until an optically translucent suspension was
obtained. Each sample was diluted with water to 750 Ill. The
peptide-vesicle sample was added to a 1 mm cell, and
ultraviolet absorbance was read from 190 to 255 nm, being
less than 1. 0 unit through that range. Far UV CD spectra
were obtained on a Jobin Yvon Mark 5 Circular Dichrograph
(Instruments SA, Metuchen, calibrated with
(+ )
10-NJ)
camphorsulfonic acid. Each plotted spectrum represented an
average of 3 to 5 spectra measured after subtracting the
buffer blank.
An Apple lIe computer and program CD MAK V (Instruments
SA, Metuchen, NJ) was used to control the CD measurement and
data process ing, including converting raw data observed
ellipt ici ty, into peptide concentration adjusted data
(mo 1 a r ellipticity, (9JA,) . werePept ide concentrations
determined analysisamino acid methodthe same
described on page 37. Aliquots of the peptide samples were
taken directly from the CD cell to determine the actual
peptide concentration. The results of different aliquots
from the sample the error of peptideshowed thatsame
concentration measurement was less than 3% (data not shown).
For peptides with CD spectra of a-helix, indicated by
minima at 208nm and 222nm, percentage helicity was calculated
from (9)222nm according to the following formula:
% a-helix = (((9)222-3000) /-39000) x 100.
This equation (Taylor & Kaiser, 1987) assumed limiting
values of (9)222nm = 3000 deg cm /dmol for 0% helix and
(9)222nm = -36000 deg cm2/dmol for 100% helix. These values
were derived from the spectra of standard peptides which were
known to adopt particular secondary structures (Greenfield &
Fasman, 1969) . This method assumed the validity of the
standard spectra and was certainly subject to error, but its
value lies in the use of the results for general, comparative
purposes (Taylor Kaiser, 1987). studies, theIn our
pattern of CD spectra was first examined and the percentage
helicity was only calculated as a relative indicator to
describe the different helix-forming tendencies of those
peptides which showed a-helical CD spectra.
Anti-peptide Antisera
The reverse phase-HPLC (RP-HPLC) purified peptides were
coupled to keyhole limpet hemocyanin (KLH) with 1-ethyl-3- (3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC). The
peptide (4. 8 mg) in 600 l H20 (pH 3. 0, adjusted with HCl)
was incubated with 2. 8 mg of EDAC in 5. 4 ml H20 (pH 3. 0) for
15 min at OOC . 'JA solution of 24 mg carrier protein (KLH) in
5 ml of H20 (adjusted to pH 9. 0 with (NH4) 2C03) was added,
and with constant stirring was incubated for 3 hr 
at OOC
(Tamura et al., 1983) . The peptide-carrier conjugate was
then dialyzed for 2 days against PBS, with frequent 
solution
changes.
Rabbits were bled twice before immunizations began.
peptide conjugates, containing 150 j.g of peptide, were
injected with complete Freund' s adjuvant into New Zealand
albino rabbits, boosted with peptide conjugate in Freund'
incomplete adjuvant and bled at periodic intervals.
Dot Blots
Peptide conjugated to bovine serum albumin (BSA) was
deposited with vacuum on nitrocellulose membrane using a
Minifold" blotting apparatus (S & S, Keene, NH). After the
membranes were blocked by incubation in 3% BSA/Tris buffered
saline (TBS) solution for 1 hr, they were incubated overnight
with a serial dilution of the respective antisera. Following
washing, the strips incubated for withwere
(125I)protein A in 0. 05% solution of Tween 20 in TBS, allowed
to dry, and exposed to film.
ELISA
Between 0. 25 and 8. 0 j.g of peptide was deposited on each
well of a 96-well microtiter plate. After washing, the
remaining surf e was blocked with BSA. Antisera, diluted to
levels, incubated wells roomthewere
temperature for min. washing, dilutionAfte r
horseradish peroxidase-coupled goat anti-mouse antibodies was
added to each well and incubated at room temperature for 
hr. After washing again, the substrate solution, 2, 2 ' azino-
di- (3-ethyl-benzthiazoline-sulfonate) (ABTS) was put in the
we 11 s . After 10 to 20 min, a green color was developed in
the wells and the intensity of each well was read directly by
microplate reader MR600 (Dynatech, Alexandria, VA)
wavelength 410 nm.
Class II-MHC Purification
Class II-MHC proteins were purified as described by
Buus al. (1986a, 198 6b) with modifications.some
Detergent-solubilized cell lysates were passed through an
affinity chromatography co 1 u (Antibody Or iented Kit,
Pierce) coupled with anti-human Ia mAb L243. Then, the
column was washed with 15 column volumes of PBS containing
5% NP-40 and 0. 1% SDS, followed by 2 column volumes of PBS
containing 1% n-octyl-glucoside (OG). Finally, the class II
MHC molecules were eluted with 0. 05 M diethylamine in 0. 15 M
NaCl containing 1% OG (pH 10). A half-volume of 0. 1 M Tris,
15 M NaCl (pH 6. 8) was added to the eluate to reduce the pH
to -7. The fractions with eluted class II MHC were pooled,
dialized against the PBS and lyophilized.
Peptide Crosslinking to Purified Class II MHC
The Ii-3 peptide was cuupled with cross linker 
hydroxysuccinimidy 1-4 -azidoben zoate ( HSAB ) by established
methods (Massague et al., 1981). Briefly, the peptides (325
ro) were incubated with HSAB (360 ro in 2% DMSO) in O. 01 
sodium phosphate buffer, pH 7. 4, with 0. 15 M NaCl for 30 min
at OOC in the dark. The reaction was quenched with 40 ro
glycine.
The peptides iodinated us ing the Enzymobeadwere
radioiodination reagent (Bio-Rad, Richmond, CA) according to
the manufacturer s instructions. The peptides were freshly
iodinated immediately prior to each experiment.
HSAB- coupleq and radio iodinated peptides ( 50 nM) were
incubated in the dark at 20 C with affinity purified class II
MHC (100 nM) Tr is-HCl buffer, pH7 . containing
Triton X-100, mM NEM and mM PMSF. Samples were
crosslinked by exposure to short wavelength ultraviolet light
for min subjected SDS-polyacrylamide geland
electrophoresis and autoradiography.
CHAPTER III
RUCTURAL STUDIES ON THE ROLE OF RECURRNT HYDROPHOBIC RESIDUES
'\'
IN CATALYZING HELIX FORMTION BY T CELL-PRESENTED PEPTIDES.
Theoretical Analysis.
pheet projection of an a helical structure. The a-helix
is a rod-like structure with the tightly coiled polypeptide
backbone forming the inner part of the rod and the side
chains extended outward in a helical array. Each amino acid
is related to the next one by a translation of 1. 5 A along
the helix axis and a rotation of 100 , which gives 3. 6 amino
acid residues per turn of helix. Therefore, amino acids
spaced three and four apart the linear sequence are
spatially qu it e close one another this conformation
while amino acids two apart the linear sequence are
situated on opposite sides of the helix and are unlikely to
make contact (Stryer, 1981).
In order to have a simple and relatively efficient
method visualize the a-helical pat tern short
P91ypeptide sequence, a method known as the sheet projection
was developed to present such a structural relationship among
the residues of an a-helix (Fig. 3 . 1) .
Graphically, the a-helix could be divided longitudinally
into four quadrants. The sheet projection represented a flat
display the helix being arbitrarily bet weencut
longitudinal quadrants one and four. This type of projection
offered a better way to analyze the side chain interactions
among the neighboring residues than the classical Edmundson
wheel plot Schiffer & Edmundson, 1967) . The Edmundson
projectio looking at a helix from the N-terminus, placed
all of the residues from one longitudinal quadrant into a
narrow arc of the wheel flat plane even though someon a
neighboring" residues in the wheel projection were actually
2-3 cycles away. The sheet projection easily demonstrated
potential salt bridges between positively and negatively
charged residues in close proximity. The positioning of
charged residues projection offeredsheet also
information whether they stabilized or opposed theabout
macrodipole of an a-helix. importantly, the sheetMost
projection could be used to identify certain types of amino
acids which had a tendency to recur wi thin one or another
quadrant. T cell-presented peptides, as shown below, tended
have recurrent hydrophobic residues wi thin one
longitudinal quadrant if the peptide coiled as an a-helix.
Quadrant III of the sheet projection in Fig. 1 represented
such an hydrophobic quadrant, or hydrophobic strip-of-helix
as it was more commonly called in our articles.
LINEAR
O.60
HELICAL
WHEEL
IV 0
SHEET
II 0IV 
Fig. 3. Sheet projection and other graphical methods
to present an a-helical structure. The squares represent
hydrophobic residues.
SOHHI /SOHHA/SHA. In order to determine quantitatively
whether a protein fragment would be selected as a T cell-
recognized epitope, a new hydrophobicity index, the strip-of-
helix hydrophobicity index (SOHHI), was proposed (Elliott et
al. 1987). The SOHHI was defined as the mean hydrophobicity
(from Kyte-Doolittle values) of set of amino acids in a
longitudinal strip down one side of a helix for 3 to 6 turns,
at positions of n, n+4, n+7, n+11, n+14 and n+18 in a protein
sequence. The SOHHI was reported at position This
computation yielded the mean hydrophobicity of residues lying
along a strip within +/-45 of the indexed residue in up to
six successive turns of a helix. This index evaluated only
hydrophobicity in a strip along the side of a hypothetical 
helix and ignored the contributions to a hydrophobicity
moment from hydrophilic or hydrophobic side chains elsewhere
the helix. Therefore this index measured periodic
hydrophobicity and not amphipathicity as defined by DeLisi
and Berzofsky (1985).
The strip-of-helix hydrophobicity algorithm (SOHHA) ,
which ranked peptides according to SOHHI calculated over 3 to
6 turns of a helix, was packaged in a computer program, and
was used to identify 10 of 12 known T cell-presented peptides
in seven well- studied proteins available at that time (Stille
et al., 1987). The SOHHA could be adapted to analysis of 310
helices (positions n, n+3, n+6, n+9, n+12, n+15) or beta-
pleated sheets (n, n+2, n+4, n+6, n+8, n+10) (Reyes et al.,
1988) .
A derivative the SOHHA, the structural helices
algorithm (SHA) , further developed to test for thewas
prediction of helices in 35 crystallographically defined
proteins (Reyes et al., 1989). In comparison with other two
leading predictive methods (Chou & Fasman, 1978; Garnier et
al. 1978) , SHA was slightly less sensitive but mo,the
efficient in the prediction of protein helices (Reyes et al.,
1989) .
The above theories were established with the effort of
many people in the laboratory during the past 4 years.
particular, I proposed to take into account the roles of
certain specific amino acid residues in these algorithms.
For SOHHA, I observed specific positioning of lysine residues
at or near the C-terminus of the reported T cell peptides,
i. e., in 7/12 cases such lysine residues were in +1 position
from the last hydrophobic amino acid in a presumptive, axial
hydrophobic strip and in +3 position in 4/12 cases. For the
SHA, I initiated the data analysis to examine whether Pro,
Gly and had position wi thin helicalpreferenceAsn
st ruct ure . This work was finished by other members in the
lab and led to the addition of "capping rules " in the SHA,
i. e. the N-terminal preference for Asn and Pro and the C-
terminal preference for Gly in an a-helical structure.
f/'
This
analysis was confirmed and extended in more detail by the
studies of two other groups (Presta & Rose, 1988; Richardson
& Richardson, 1988)
Sensitivity and efficiency of SOHHA. Predictions made
with the SOHHA, the amphipathicity algorithm (DeLisi
Berzofsky, 1985) and the motifs algorithm (Rothbard & Taylor,
1988) were compared to peptides which had been experimentally
determined to be cell-presented (Table 2) .and
Sensitivity the fraction cell-presentedknownwas
peptides which were predicted by each algorithm. Efficiency
was the fraction of the predictions which correctly identify
T cell-presentedpeptides by an algorithm.
The sensitivity and efficiency of each algorithm to
predict T cell-presented sequences were determined in terms
of the degree . of two measures of proximity, varying in
stringency. The more stringent level "overlapping" occurred
when the intersection of the experimental and predicted
segments was 50% or more of the union of the two segments.
For example, if the true segment occupied sequence positions
1-10 and the prediction occupied positions 4-13, then the
union of the two covered 1-13, while the intersection covered
4 through 10 (7 positions), and 7/13 exceeded 50%. At the
less stringent level, " touching" was defined as a non-empty
intersection of two segments, the predicted and the known.
The two levels of stringency were "nested" in the sense that
touching included overlap.
Table 3. 1 and 3. shows one of such analyses with 
well- studied proteins. the more stringent level of
comparison, sensitive (0. 43) thethanSOHHA was more
amphipathicity (0. 29) and motifs (0. 0 and 0. 0) predictions,
and more efficient (0. 35) than amphipathicity and(0. 14)
mot i f s ( 0 . 0 and O. 0 ) predict ions. At the less stringent,
touching criterion, the amphipathicity (0. 71) was
sensitive as Rothbard-5 (0. 79) and more sensitive than SOHHA
(0. 57) and Rothbard-4 (0. 43) . At that criterion, the SOHHA
was more efficient (0. 47) than the amphipathicity (0. 36) and
motifs (0. 25, 0. 40) methods.
TABLE 3.
Experimentally Determined and Predicted T-cell Epitopes
for Five Well-Studied Proteins
PROTEIN KNOWN SOHHA
AMPHIPA MOTIF-4 MOTIF-!THICITY
Chicken 258-273 23- 12- 104-108
Ovalbumin 323-339 79- 33- 13- 370-374
216-230 50- 55-
323-337 80- 85-
115-128 95-
138.159 116-119
250-269 123-126
300-312 143-146
315-319 155- 158
334-341 182- 185
186-189
199-202
215-218
218-221
228-231
237-240
263-266
266-269
301-304
304-307
328-331
340-343
350.353
370-373
Chicken 46- 106- 120 15- 19- 105.109
Lysozyme 79- 63- 72-
81- 95- 115-118
108- 119 109- 115
Horse 45- 14- 18-
Cytochrome 66- 45- 45-
57. 66- 56-
71- 1 00- 1 03 62-
73-
93-
Sperm Whale 68- 21- 11- 20- 12-
Myoglobin 106- 112 123- 137 28- 31- 27-
132- 146 131- 145 58- 38- 73-
69- 93- 109- 113
1 04- 112 102- 105 141- 145
118-123 105-108
133-140 129-132
133- 136
136-139
S. aureus 51- 17 - 24-
Nuclease 61- 25- 45- 21- 101-105
81 - 1 00 58- 63- 24-
91. 110 65- 78- 64-
85- 111-114 88-
121-124 97-100
107-110
110- 113
r/'
TABLE 3.
Comparisons of Methods to Predict T-cell Epitopes.
Evaluated with Five Well-studied Proteins
PROTEIN
AMPHIPA MOTIF-4 MOTlF.THICIT
T-cell EpitopesOO
total
Mean number/protein (1. 3.4 (1. 8 (3. 6 (8.4) 2 (2.2)
Mean length/protein 16.2 (3. 15.0 (0. 10.2 (5.
Predictions
Overlapping
Touching
Sensitivity'
Overlapping 0.43
Touching
EfficiencyS
Overlapping
Touching
.. Chicken ovalbumin, chicken lysozyme, horse cytocorme, sperm
whale myoglobin and staphylococca nuclease.
00 Numbers shown in parenthesis are SO.
Correct predictions/number of known epitopes.
Correct predictions/number of predictions.
Structural Studies of a Group of HPLC-Purified Peptides
Peptide description. In order to test whether the axial,
hydrophobic strip per se could promote helix formation, the
secondary structures of a series of HPLC-purified peptides,
which were prepared for different purposes and varied 
likelihood for T cell presentation according to experimental
reports and predict i algorithms, were evaluated by 
analysis in phosphate buffer, in phosphate buffer with 45%
trifluoroethanol ( TFE) , and in phosphate buffer with di-o-
hexadecyl phosphatidylcholine (DHPC) vesicles.
The sequences of these peptides varied greatly (Table
3) as did their SOHHI and mean hydrophilicity (Table 3.
values. Influenza virus matrix prote in and(57-72)
nucleoprotein (336-356) were presented by human class I MHC
alleles to cytotoxic T lymphocytes (Gotch et al. , 1987;
McMichael et al., 1986). Influenza virus hemagglutinin (493-
513 ) was predicted by the SOHHA to be a T cell-presented
peptide and touched the sequence of the H-2K restricted T
cell epitope hemagglutinin (512-528).
Two peptides (MA-2 and MA-3) from the Epstein-Barr virus
membrane ant igen gp350/220 selected forMA)(EBV were
development of neutralizing antibodies based on their high
hydrophilicity in a Hopp-Woods analysis and the presence of
prolines which might create stable ~-turns in both the native
PEPTIDE NAME
Prototypic
Invariant chain
(148-164, Tyr162)
Invariant chain
(Tyr + 78-92)
Influenza hemagglutinin
(513-528)
Influenza matrix protein
(57-72, +Tyr)
Influenza nucleoprotein
(336-355, + Tyr)
EBV MA gp350/220
(807 -816)
EBV MA gp350/220
(718-729 , + Tyr)
Murine CD-
(88-101, +Tyr)
TABLE 3.
Sequence of Peptides
ABBREVIATION
PH- YOELOKL TQTLK
1i- ENLRHLKNTMETIDYKV
li- YRMKLPKPPKPVSKMR
NREKVDGVKLESMGIY
KGILGFVFT TVPSERY
AAFEDLRVLSFIRGTKVSPRY
MA- STTPRPRYNA
MA- SSPEPRPGTTSEY
MT11- GTNGMTRLEKDLDVY
protei and the KLH-conjugated peptides. Both MA-2 and MA-3
had low SOHHI values and multiple prolines which might be
against helix formation.
Two pept ides from invar iant chain sequence were
included . Ii-3 was synthesized to test the hypothesis that
this segment of Ii was an amphipathic helix which might cover
the class II MHC desetope until charging of a foreign peptide
(Elliott et al. , 1987a, 1987b) . Ii-4 was synthesized to
raise an anti-Ii antiserum because of its almost palindromic
sequence highlighted by 6 positively charged residues on a
tightly kinked structure induced by 4 prolines.
PH-1 . 0 was designed as a prototypic helix model to test
the hypothesis ,of SOHHI. It was constructed with a narrow
and strong hydrophobic strip with 4 leucines along one side
of a putative a-helix. MT11-A was synthesized from the
murine CD2 sequence and used as a negative control for PH-1.
because MT11-A had a mean hydrophilicity very similar to PH-
0, but its maximal SOHHI was low (Table 3. 4).
Results of CD analysis. Structural order the
peptides are summarized in Table 3. In phosphate buffer
all of the nine peptides in this group were in a random coil
conformat ion. This was expected because none of the peptides
here was end-blocked and unblocked peptides were reported to
TABLE 3.4
SOHHI and Mean Hydrophilicity of Peptides
PEPTIDE SOHHI* MEA HYDROPHILICITY
PH- + 0.
li- + 1.
1i- 1.40 + 1.
+ 0.
- 0.
+ 0.
MA- + 1.
MA- + 1.
MT11- + 0.
The maximal SOHHI through the most hydrophobic strp
found in sheet projections of each peptide.
TABLE 3.
CD Measurement of Peptides
Phosphate Buffer Lipid Vesicles
PEPTIDE (8)222nm Helici (%) (8)222nm Herdy (%) (8)222nm Helic (%)
PH- 918 19,660 11,210
Ii - 367 16,780 -4,000
Ii - 5,404 171 5,459
720 140 1 ,180
1 ,21 0 937 107
879 22,070 319
MA- 227 210 5,421
MA- 2;509 722 593
MT11- 152 600 520
Percentage helicity was calculated only for peptdes with CD
spectra shown clear a-helical pattern.
not form stable a-helix in aqueous solution (Bierzynsky et
al., 1982; Shoemaker et al., 1987).
In 45% TFE buffer, CD spectra showed three group of
peptides,
tendencies.
with high, low helix-formingmoderate
By the formula of Kaiser et al. (1987), PH-1.0,
Ii-3, and NP had 58%, 51% and 64% calculated helicities,
respectively. CD spectra with helical pattern were also
found with HA and MX peptides, with 23% and 18% calculate
helicities, respectively. Peptides with multiple prolines
(Ii-4, MA-2, MA-3) or with relatively low SOHHI (MT11-A) did
not show recognizable a-helical CD spectra. Each experiment
was repeated at least 3 times and the (6)222nm values were
collected as the average of 3-5 measurements. Fig. 3 . 2 shows
CD spectra of NP, HA and Ii-4 in both phosphate buffer and
TFE solution, representing high, and low helixmoderate
formation respectively.
Structural order of peptides in the presence of lipid
vesicles was further tested to assess the degree to which
hydrophobic surface might catalyze formation of helices or
other structures. The lipid vesicles were made by a simple
technique described by Vogel (1987, 1988) and had negligible
contribution to the CD spectrum when the lipid vesicles were
measured (Fig. 3) . Except ing MX, all the otheralone
peptides showing helix formation in TFE solution maintained
their tendencies in the presence of lipidhelix-forming
but with a lower percentage of helicity Table
5) . The prototypic helix peptide PH-I. O maintained 36%
helix formation in lipid vesicles in comparison with 58% in
TFE, while other peptides had less than half of the helicity
formed in lipid vesicles than that in TFE solution. The CD
spectrum of peptide MX in lipid vesicles was typical of 
sheet st ruct ure . Its pattern could not rule out a minor
degree of helical content, but did indicate a stronger ~-
sheet component. Ii-4, MA-2, MA-3 and MT11-A still did not
show a helical pattern in the presence of lipid vesicles.
spectra of NP, MX and MA-2 in lipid vesicles are shown in
Fig. representing a-helix, sheet and random coil
structures, respectively.
The results from lipid vesicles experiments suggested
that lipid ves icles, resembling natural conditions, might
represent a more stringent helix inducing environment than
TFE which, by decreasing the dielectric constant of the
buffer, only enhanced intrapeptide interactions generally.
In the presence of lipid vesicles, the peptides might depend
more on their SOHHI to form a helical structure than in TFE.
Among peptides forming a-helices in the presence of vesicles,
percentage helicities calculated from the CD spectrum were
proportional to the SOHHI (r=0. 77) (Fig. 4) . Wi th the
sample size of 5, the p value came close to significance,
p=O. 07 .
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Fig. 3. Circular dichroism spectra of NP, HA, 1i-4 in 10 mM
phosphate buffer (8) and that buffer with 45% TFE (T at room
temperature.
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Fig. Circular dichroism spectra of NP. MX. 1i-4 in the
presence of lipid vesices (V) at room temperature. The unmarked
curves are the vesicles-only control specra.
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Fig. Correlation between percentage helicity and SOHHI.
Percentage helicity (Table 3.5) In the presence of vesicles is
plotted for PH-1.0, 11-3, HA, NP, and MT11-A as a function of
maximal SOHHI (Table 3.4).
Structural Studies of Prototypic Helix Peptide PH-1.
ept ide design. PH-1. designed in order towas
establish a putative model to test the validity of 
SOHHI
theory and examine important biophysical principles
governing the formation of peptide secondary structures when
the peptide was in close contact with a hydrophobic surface.
AS the initial step, PH-1. 0 was designed with simply 6 types
of amino acids (Fig. 5) . If PH-1. 0 could coil as an 
helix, it would have an axial strip of maximal hydrophobicity
made by 4 leucine residues. A potential salt bridge between
Glu 4 and Lys 7 could link the helical loops of the peptide.
putting a negatively charged residue (GIU4) close to the N-
terminus and a positively charged residue (Lys13) at the C-
terminus could help stabilize the a-helical structure of the
peptide through favorable interactions with the macrodipole
of the helix. The inclusion of a C-terminal lysine residue
was also consistent with the finding that T cell-many
presented peptides had a lysine at or near the carboxyl
terminus al. , 1987) . Tyr serve twocould( Spouge
purposes: (a) radioiodination the pept ide for other
biochemical st udies, such the binding PH-1.
purified MHC molecules; (b) spin-labeling of the peptide by a
nitroxide- containing molecule allow electron spin
resonance (ESR) study of interactions between the peptide and
PH-
GLNII GLU
III LEU LEUIV " TYR
GLN
THR
LEU
LYS
GLN
LYS
LEU
THR
Fig. Sheet projection of the sequence of prototypic
helix peptide PH-l.
Ci hydrophobic surface. Relatively hydrophilic, uncharged
residues, glutamine and threonine, were placed in other
positions of the PH-1. 0 sequence.
termini of the peptide because
We did not block N- and C-
our major interest was
for the scavenging of proteolytic fragments of
protei antigen during antigen processing and presentation.
:Work ing hypothesis. We hypothesized that the helix
formation of a short peptide might be catalyzed by the helix
stabilization effect of anchoring hydrophobic residues on the
successive loops of a growing helix to a nearby hydrophobic
surface. Fig. 6 depicts such a process with PH-1. 0 as the
model peptide.
1 . 0 in phosphate buffer and in lipid vesicles. The
secondary structure of PH-1. 0 was measured by CD in phosphate
buffer and phosphate buffer with di-O-hexadecyl
phosphat idylchol ine (DHPC) vesicles with MT 11- A the
control peptide (Fig. 7). PH-1. 0 and MT11-A were similar in
several including length (Table 3) , meanaspect s,
hydrophilicity ( Tab 1 e 4) , retention time in the same
reverse phase-HPLC column (Fig. 3. 8), but differed in their
SOHH I Table result the differentvalues
distribution patterns of hydrophobic residues (Fig. 3. 9) .
E L K LT
- -
I - 
III I I1 I111
alii
Fig. 3. Helix formation can be stabilzed by recurrent hydrophobic
residues which creat an axial , hydrophobic strip when the helix is
formed against a hydrophobic surface.
PH -
2.0
-2.0
MT11-
22 240 20 220
WAVELENGTH (ru
240
Fig. Circular dichroism spectra of PH- O and MT11-A in 10
mM phosphate buffer (B) and in that buffer with lipid vesicles M at room
temperature. The unmarked curves are the vesicles only control spectra.
. It III""
Fig. 3. Chromatograms of purified PH- 0 (upper panel) and MT11-
(lower panel) analyzed by a same reverse phase HPLC system using
1% TFA as the starting buffer and Increment of ACN at 1o/Jmin, flow
rate 1 mVmin.
PH -1 . 0
MT 11- A
IV 
E // Y 
D II
L G
Fig. Wheel plots for PH-1.0 and MT ll-A. The
hydrophobic residues are shown in bold fonts.
In 0. 01 M phosphate buffer alone both PH-1. 0 and MT11-A
could not form an a-helix while in the presence of lipid
vesicles PH-1. O but not MT11-A, demonstrated a distinct
helical spe ct rum (Fig. 7) . Th us, the ability of a
peptide to form an a-helical structure in lipid ves icles
appeared to relate to the pattern of recurrent hydrophobic
residues in the sequence.
The possibility of aggregation of PH-1. 0 peptide was
tested by measuring the molar ellipticity of PH-1. 0 at high
concentrations of salt and/or peptide. The results showed
that no helicity was induced when PH-1. 0 concentration was
increased either g / ml 400 g/mlfrom
phosphate buffer or from 82 g/ml to 200 g/ml with the
addition of 1 M KCl (Fig. 10). Thus, helicity under these
conditions could not be induced via self-association of PH-
0 through their axial hydrophobic strips.
0 in TFE so ution. PH-1. 0 could form a-helix
TFE solution (Fig. 11). CD measurements were carried out
immediately after the addition of various amount of TFE to
the non-helical peptide sample in phosphate buffer and the CD
spectra demonstrated that the transition from random coil to
helix had been completed (Fig. 11) . TFE was used as a
stabilizer to maintain the stability of intermediates in the
peptide folding react ion this stability mightand
/!.
important in both helix initiation and propagation. The
higher the concentration of TFE, the more peptides formed 
helix (Table 3. 6).
Temperature dependence of helicity. Helix formation for
PH-l. O in TFE or in lipid vesicles was temperature-dependent
with a higher percentage of a-helix formation lower
temperatures (Table 3. Fig. 12) . In TFE, there was a
smooth decrease of helicity found in the CD spectra from 4
(76% helicity) to 7SoC (38% helicity). In the presence of
lipid vesicles, PH-l. O formed 32% helicity at 25 C while no
helicity was observed when the temperature was raised to
above 50 C, perhaps reflecting the changing organization of
the lipid vesicles.
The clean isodichroic point at 202 nm in CD spectra of
peptides in TFE or lipid vesicles (Fig. 3 . 12) suggested that
the transition from a-helical to random-coil was two- state,
so that each amino acid was in either a helical state or a
random-coil state.
PH-1.
200 210 220 230 240
WAVELENGTH (nm)
Fig. 3.10 CD spectra of PH- 0 in 0.2 M phosphate buffer with
peptide concentration at 82 mglml (L), at 400 mglml (H) and at 200
mglml with addition of 1 M KCI (K).
f/'
PH-1.
E -2.
MT11-A
2.0
20 220 240
Wavelength (nm)
Fig. 3.11 CD spectra of PH- 0 and MT11-A in 10 mM phosphate
buffer (B) and that buffer with 45% TFE (T at room temperature.
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TABLE 3.
Percentage Helicity Formed in Different TFE Concentrations
PH- MT11-
TFE* (8)222 nm (8) 222 nmHelicity Helicity
849 157
30% 21,530 910
45% 22,240 1 , 600
* Expressed as percentage of TFE in 10 mM phospate buffer.
'i 40
I 20
:2 0.0
--20
-40
e 2.
0.0
- -2 0
-4. 200 220 240 200 220 240
Wavelength (nm)
Fig. 12 CD spectra of PH- 0. Panel A: 10 mM phosphate buffer
alone (B) and with PH- 0 (PB) at 4 C. Panel B: PH- 0 in 10 
phosphate buffer with 30% TFE at different temperatures. Panel C: lipid
vesicles alone (V) and with PH- 0 at 4 C. Panel D: PH- 0 in lipid
vesicles at different temperatures. Spectra shown in panels A and Care
raw data unadjusted by peptide concntration.
TABLE 3.
Percentage Helicity of PH- 0 at Different
Temperatures
Temperature
300/0 TFE Lipid Vesicles
(8)222 nm % Halicity (8) 222 nm % Halicity
2SoC
sooc
7SoC
26,490
510
16,060
11,860
12,490
9,422
Structural studies of PH-1. 0 analogs.
Analogs of PH 1. o. The strong helix-forming tendency of
PH- 0 prompted us design more analogs of PH-1. 0 to
analyze systematically the contribution of each residue to
the formation of a helical structure in the presence of lipid
vesicles. As part of a general plan, at least the following
analogs should be considered.
Leucine residues in the axial hydrophobic strip of PH-
1. 0 could replaced with non-hydrophobic, non-bulky
residues such as threonines (Fig. 13) . Such a replacement
could be made simply at one leucine or jointly at two or more
leucines at the same time. This type of change was expected
to lead to a decrease in SOHHI and thus to a decrease in the
helix-forming tendencies of the peptides. It could also be
shown whether the four leucines were equally important
catalyzing the formation of an a-helix in lipid vesicles.
The next set of analogs (Fig. 14) was designed to test
whether the proposed salt bridge Glu Lys7 did contribute to
the a-helix formation for PH-1. 0 and whether the positioning
with negatively charged residue N-terminal andthe
positively charged residue at C-terminal played an important
role in stabilizing a helical structure.
Another way to show that the a-helix formation of PH-1.
depended SOHHI keep the overalldirectly was
1. Ih-Tyr-Gln-G1U-Leu-Gln-LYS-Leu-Thr-Gln-Thr-LeU-Lys
2. Leu- Tyr-Gln-G lu- Ih-Gln-Lys-Leu- Thr-G In- Thr-Leu-Lys
3. Leu- Tyr-Gln-G lu-Leu-G In-Lys- Ih- Thr-G In- Thr-Leu-Lys
4. Leu- Tyr-G In-G lu-Leu-G In-Lys-Leu- Thr-Gln-Thr-Ih-Lys
5. Ih-Tyr-G In-Glu- Ih-G In-Lys-Leu- Thr-G In- Thr-Leu-Lys
6. Ih-Tyr-G In-Glu-Leu-G In-Lys-Ih- Thr-Gln-Thr-Leu-Lys
7. Ih- Tyr-G In-Glu-Leu-G In-Lys-Leu- Thr-G In-Thr- Ih-Lys
8. Leu-Tyr-Gln-G lu- Ih-G In-Lys-Ih-Thr-Gln-Thr-Leu-Lys
9, Leu-Tyr-Gln-Glu-Ih-G In-Lys-Leu-Thr-Gln-Thr-Ih-Lys
10. Leu- Tyr-G In-G lu-Leu-G In-Lys- Ih- Thr-G In- Thr- Ih-Lys
1.11. Ih-Tyr-Gln-Glu-Ih-Gln-Lys-Ih-Thr-Gln-Thr-LeU-Lys
1. 12. Leu-Tyr-G In-Glu-Ih-G In-Lys-Ih-Thr-Gln-Thr-Ih-Lys
13. Ih-Tyr-Gln-Glu-Ih-Gln-LYS-LeU-Thr-Gln-Thr-Ih-LYS
14. Ih-Tyr-Gln-Glu-Ih-Gln-Lys-Ih-Thr-Gln-Thr-Ih-Lys
Fig. 3.13 Analogs of PH- 0 with changes at the axial hydrophobic strip.
1. Leu-Tyr-Gln-Ih-Leu-Gln-LYS-Leu-Thr-Gln-Thr-Leu-Lys
2. Leu- Tyr-Gln-G lu-Leu- G In- Ih-Leu-Thr-Gln- Thr-Leu-Lys
3. Leu- Tyr-Gln- Ih-Leu-G In- Ih-Leu- Thr-G In- Thr-Leu-Lys
4. Leu- Tyr-G In-G lu-Leu-G In- Ih-Leu- -G In- Thr-Leu-Lys
5. Leu- Tyr-G l -Leu-G In-Lys-Leu- Thr-G In- Thr-Leu-Lys
6. Leu- Tyr-G In-G lu-Leu-G In-GW-Leu- Thr-G In- Thr-Leu-Lys
7. Leu- Tyr-G In- -Leu-G 1 n-fU-Leu- Thr-G In- Thr-Leu-Lys
8. Leu- Tyr-G n-G u-Leu-G n-L ys-Leu- Thr-G In- Thr-Leu- 
9, Leu- Tyr-G In-Glu-Leu-G In-Lys-Leu- Thr-G In- Thr-Leu-
10. Leu- Tyr-G In-G lu-Leu-G In- Ih-Leu- Thr-G In- Thr-Leu- 
1 1. Leu- Tyr-G In- Ih-Leu-G In-L ys-Leu- Thr-G In- Thr-Leu- 
12. Leu-Tyr-Gln-Ih-Leu-Gln-Ih-Leu-Thr-Gln-Thr-Leu-
13. Leu- Tyr-G In- -Leu-G In-GW-Leu- Thr-G In- Thr-Leu-
Fig. 3.14 Analogs of PH-1 .0 with changes made to break the potential
salt bridge and to counteract with the macrodipole of peptide.
composition of the peptide but to exchange residues between
the hydrophobic strip and its opposite hydrophilic strip,
such as PH-3. 1 shown in Fig. 15. this analogHoweve r ,
involved two changes at the same time and thus it might be
necessary to first test what would be the effect of each
change alone (PH-3. 2 and PH-3. 3) to the structure of peptide
(Fig. 15. A) .
Since we hypothesized that the axial, hydrophobic strip
in PH-1. 0 stabilized an a-helical conformation against lipid
vesicles, it was worthwhile to test whether alternatively
placed hydrophobic residues in other positions might compete
to decrease the helical structure component of a peptide.
PH-1. such analogs PH-4. could be produced by(e. g. ,
substituting glutamines at quadrant I with leucine residues
(Fig. 15. B) . Some of these analogs might have to break the
potent ial br idge GIU 4_Lys in order to achieve asalt
competitive effect and this could be tested by simultaneously
making changes at position 4 or 7 with uncharged residues.
Nine pept ide s synthesized above possiblewere from
analogs (Fig. 16) with major interest on the number and
placement of hydrophobic residues required to induce PH-l.
to form a helical structure in lipid vesicles. Thus, only
one or two changes were made with hydrophobic residues for
each peptide, leaving the salt bridge and other important
structural features untouched. We did not synthesize all the
:;z
1. Leu-Tyr-Gln-Glu-Leu- -Lys- -Thr-Gln-Thr-Leu-Lys
2. Leu- Tyr-G In-G lu-Leu- -L ys-Leu- Thr-G In- Thr-Leu-L ys
3. Leu- Tyr-G In-G lu-Leu-G In-Lys- - Thr-G In- Thr-Leu-Lys
4. 1. Leu- Tyr-G In-G lu-Leu- -Lys-Leu- Thr-G In- Thr-Leu-Lys
2. Leu- Tyr- -G lu-Leu-G In-L ys-Leu- Thr-G In- Thr-Leu-Lys
4.3. Leu- Tyr-G In-G lu-Leu-G In-Lys-Leu- Thr- - Thr-Leu-Lys
4. Leu- Tyr-G n- Ib-Leu- -Lys-Leu- Thr-G In- Thr-Leu-Lys
4.5. Leu- Tyr- Ib-Leu-G In-Lys-Leu- Thr-G In- Thr-Leu-Lys
6. Leu- Tyr-G In- Ib-Leu-G In-Lys-Leu- Thr- - Thr-Leu-Lys
7. Leu- Tyr-G In-G lu-Leu- !h-Leu- Thr-Gln- Thr-Leu-Lys
4.8. Leu- Tyr- -G lu-Leu-G In- !h-Leu- Thr-G n- Thr-Leu-Lys
4.9. Leu- Tyr-G In-G lu-Leu-Gln- Ib-Leu- Thr- - Thr-Leu-Lys
10. Leu- Tyr- -G lu-Leu- -Lys-Leu- Thr-G In- Thr-Leu-Lys
Fig. 3.15 Analogs of PH- 0 with alternately placed hydrophobic residues
to compete with the axial hydrophobic strip.
peptides with two or more leucines substituted as originally
proposed in Fig. 3. 13 because the set should becurrent
sufficient to achieve same goal, and practically it would be
too expensive to synthesize all the analogs. However, we did
synthesize PH-4. 2 as an initial step to test the competitive
force against the axial hydrophobic strip to interact with
lipid vesicles.
CD spectra of analogs in phosphate buffer and in TFE.
None of the analogs, as with PH-1. 0, formed a-helix in 10 ro
phosphate buffer alone (Fig. 3. 17) . In 10 ro phosphate b ffer
with 45% all the analogs exhibited 35-43% helicityTFE,
(Fig. 3. 17, Table 3. 8). Two of the analogs, PH-1. 1 and PH-
2, were further analyzed for their temperature dependent
patterns of helix formation in TFE solution. For both
peptides, the CD spectra showed a smooth decrease of helicity
from 4 C to 75 C and again a clean isodichroic point at 202
nm was found (Fig. 18). In comparison with PH-1. (Table
7), these two analogs consistently formed less helicity at
same temperature (Table 3. 9), suggesting they might not coil
as well as PH-1. 0 in these experimental conditions.
PH-
PH- 1 .
PH-
PH-
PH- 1.4
PH- 1 .
PH-
PH-
PH-
PH-
6. Gin 10. Gin7. Lys 11. Thr
8. Leu 12. Leu 9. Thr 13. Lys
L Q K L T Q T L K
T Q K L T Q T L K
L Q K T T Q T L K
L Q K L T Q T T K
T Q K L T Q T L K
L Q K T T Q T T K
L Y L E L Q K L T Q T L K
3. Gin
4. Glu
1. Leu 5. Leu
2. Tyr
T Y Q E
L Y Q E
L Y Q E
L Y Q E
T Y Q E
T Y Q E
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L Y Q E
Fig. 3, 16 Schematic drawing of the placement of hydrophobiC residues
(short bars) and the Thr substitutes (circles) for synthesized set of
PH-l. 0 analogs. Molecular weight of peptldes:
PH-1.0, 1605.
PH-1. 1 to 1.4, 1593.
PH-1.5 to 1.7 and 1.10, 1581.5;
PH-4.2, 1590.
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Fig. 3.17 CD spectra of analog peptides in 10 mM phosphate bufer
(B) and that buffer with 45% TFE (T at room temperature.
PH-1.
-40
PH- 4.
750
500
250
200 220
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Fig. 18 CD spera of PH-1.1 and PH- 2 in 10 mM phosphate
buffer with 30% TFE at different temperatures.
TABLE 3.
Percentage Helicity of Analog Peptides in 450/0 TFE
PEPTIDE (8)222 nm Percentage Helicity
PH- 13,770
PH- 13,640
PH- 11,220
PH-1.4 10, 800
PH- 10,810
PH- 390
PH- 12,890
PH- 11, 110
TABLE 3.
Percentage Helicity in 30% TFE at Different Temperatures
PH- PH-
Temperature (8)222 nm % Helicity (8) 222 nm % Helicity
18,240 16,580
15,080 12,850
10, 100 10,290
025 785
f!'
CD spectra of analogs in lipid vesicles. The eight
analogs with systematic substitution of threonine for either
one or two leucines in the longitudinal hydrophobic strip
demonstrated quite diverse CD spectra when the peptides were
measured in lipid vesicles. Wh i Ie of these eightnone
analogs could show a detectable helical CD spectrum at room
temperature, at least three of them formed helical structure
when the experiments were performed at (Fig. 3. 19, Table
10) . PH-1 . clear ly had helix formation with 34%
calculated helicity. PH-1. 1 could also coil as a-helix with
26% helicity. PH-1 . 7, with one minimum shifted to above 200
nm and a detectable minimum at 222 nm in comparison with
other analogs, at least partially formed a helical structure
with 21% helicity calculated from its (e1222 value.
PH-4 . 2 can form a-helix structure in lipid vesicles at
both room temperature and (Fig. 20) . lessHowever,
helicity was formed for PH-4. 2 in comparison with PH-1. 0 in
lipid vesicles (Table 3. 11) .
t''
-2.
-2.
-2.
-2.
. .
''''''0
200 220 240 200 220 240
Waveleng (nm)
Fig. 3.19 CD spectra of analog peptides in the presence of lipid
vesicles at room temperature (left panels) and at 4 C (right panels).
TABLE 3.
Percentage Helicity of Analog Peptides in Lipid Vesicles
PEPTIDE (9)222 nm Percentage Helicity
PH-1.
PH- 1 .
PH-1.
264
10,280
259
-0 -2 0
C) 
-40
-0 
-20
200 220
wavelength
240
(nm)
Fig. 3.20 CD specra of PH- 2 in the presence of lipid vesides at room
temperature (upper panel) and 4 C (lower panel).
TABLE 3.
Comparison of Percentage Helicities between
PH-1.0 and PH- 2 in Lipid Vesicles
Temerature
PH-
(8)222 nm % Helicity
PH-
(8) 222 nm % Helicity
12,490
422
260
629
Functional Studies on PH-1. 
Once we found that PH-1. 0 could coil as a-helix in lipid
vesicles, asked whether PH-1. have the funct ion 
compete with other known T cell-presented peptides to block
the antigen presentation. Dr. Dolores Jaraquemada in Dr.
Eric Long s lab (NIH) tested the PH-1. 0 peptide I prepared in
a DR 1-restricted cytotoxicity test. EBV-transformed cell
line 45. (DR 1) was used as target cell. T cell lines
109. 2B2 and 130. 1C6 were HLA DR restricted and could
recognize M1 17-31, an influenza M1 matrix protein derived
peptide (Jaraquemada et al., 1990) (Fig. 21) . CTL 109. 2B2
could lyse target cells treated with antigen peptide M1 17-31
(Fig. 22. A) . Such antigen specific lysis was inhibited by
another DR 1-restricted peptide HA 307-318 but not by a
negative control peptide ATIII (Fig. 22. B) . HA 307-318
inhibited original lysis by 60%, which was the maximum level
expected (Shimojo et al., 1989). PH-1. 0 inhibited the lysis
at the same level as H3 307-318 (Fig. 22. even though
treatment of the target cells with PH-1. 0 alone could not
induce a significant lysis (Fig. 22. C) . Similar results
were produced using different CTL line, 130. 1C6
(Fig.3 . 23) .
M1 17-
PRO ALA GLN GLU
I I 17 GLU ARG ASPIII SER LEU ISO LEU VALIV ' GLY LYS ALA
Fig. 3.21 Sheet projection of the sequence of M 1 17-31.
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Fig. 3.22 Competitive inhibition of presentation of M1 17-31 by
PH-1. 0 peptide. DR1-restricted M1 17-31 specific CTL 109. 282 was
assayed on 45. 1 targets. In the control condition (A, C), targets
were either not exposed to peptide (8), or exposed to 1 ro M1 17-31
(0), 1 ro negative control peptide ATIII (0) or 1 ro PH-1. 0 (A) for
18 hr at 370C, washed three tims, and assayed for their ability to
be lysed by an DR1-restricted CTL 109. 282. Under the competitive
inhibition conditions (8), targets were exposed to combinations of 1
ro M1 17-31 peptide plus 450 ro of either PH-l. 0 (A), or another
DR1-restricted peptide HA 307-318 ) as a positive control, or the
negative control peptide ATIII (0) for 18 hr at 370C, washed three
times, and assayed for their abilitity to be lysed by the CTL line
109. 282.
Effector to target ratio
Fig. 3.23 Competitive inhibition of presentation of M1 17-31 by
PH-1. 0 peptide. Simlar as Fig. 21 except the DR1-restricted M1 17-
31 specific CTL 130. 1C6 was used instead of 109. 2B2. Panel A and C:
no peptide (8), 1 M1 17-31 (Q), 1 negative control peptide ATIII
(0) or 1 PH-l. 0 (A). Panel B: combinations of 1 M1 17-31
peptide plus 450 of PH-1. 0 (A), plus positive control peptide HA
307-318 (A), or plus ATIlI (0).
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CHATER IV
BIOCHEMICAL STUDIES OF INVARIANT CHAIN
A. Binding of Ii (148-164) to Purified Class II MHC Molecules.
Hypothesized function of Ii (146 169) . In an analysis of
the primary sequence of Ii, a hypothetical, amphipathic 
helix found from res idue P he 14 6 to Me t 1 6 9sequence was
(Fig. 1). It had a distinctive strip of hydrophobic amino
acids along one side of the helix and otherwise generally
hydrophilic amino acids. Because it is quite unusual to have
such long (5- cycle) , hydrophobic strip,narrow
hypothesized that this 24- residue region of Ii might be a
sequence which class MHC molecules untilbound I I
dissociation in endosomes where processed foreign antigen
could be charged onto the desetope (Elliott et al., 1987a,
1987b) .
When the whole Ii protein sequence was subjected to
screening by three different algorithms which selected T
cell-presented peptides, the results further supported the
above hypothesized function this sequence.short
Al though several selected by eachsequences were
method, this region in Ii was selected by all three methods
(Fig. 2) . This 24-residue was well conservedsequence
between human'Jand murine Ii sequences (Fig. 4. 3), accepting
(11-2 )
GLU ARG ASH THR TRP146 ASH HIS THR LYSil PRE LEU LEU MET ILE VALIV PRO LYS GLU ASP PRE
(11-3)
148 GLU ARG
'\ 
ASH HIS
LEU LEU
LYS
TRP
LYS
ILE VAL
ASP
ASH THR
THR
MET
GLU
GLU MET
SER
TRP
Fig. 1 Sheet projection of peptides 1i-2(146-169) and li-3(148-164).
HUMAN II PROTEIN SEQUENCE
COOH
. , , , , , , , , , , , , , , , , , , , , , , 
,iz 
' , , , , , 
146 169
Amphlpathlclty -
SOHHA
--- - -
Motifs-4
Motifs-
Fig. 4.2 Analysis of invariant chain sequence by various
computer algorithms. The printed short lines represent
the sellections made by the respective algorithm.
- - - - - K - - - - S - D 
- - 1
- - - -
Fig. Comparison of proposed helical sequences in
human and murine Ii
.;,;':
iI.
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structurally similar residues positions whichamong
differed between these species. Thus, this segment might be
important in maintaining some function of Ii.
and Ii 3 peptides. Two peptides from the putative
helical Ii (146-169) synthesized (Fig. 1) .sequence were
First, a 24-residue peptide Ii-2 was synthesized. However,
the peptide yield was very low and only 1-2 mg of Ii-2 was
purified, just enough for rabbit immunizations. A shorter
version, Ii-3 (148-164), was then synthesized based on the
following rationales:
(a) Ii-3 started from Glu148 instead of Phe 146 since
putting a negatively charged residue closer to N-terminus
might favor the a-helix formation through its dipole. Since
proline usually was a helix breaker, removal of pro147 might
also have a positive effect on the helix formation of the
peptide as an immunogen.
(b) Ii-3 ended at Val164 with a positively charged
Lys 163 in longitudinal quadrant II and very close to the C-
terminus. it both fitted the statistical finding ofThus,
the positioning of C-terminal Lys in a T cell-presented
peptide and had a favorable interaction with the helix
dipole.
(c) Two pairs of potential salt bridges remained in Ii-
3, i. e., Glu148_His 152 , Lys 154-Glu158
,";:!-
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(d) A shorter peptide with the removal of several C-
terminal residues with unknown roles (Phe165 to Met169) would
be easier to synthesize, as well as bringing focus up on the
helical portion of the sequence.
(e) Since Trp162 was the only aromatic residue in Ii-3,
it was replaced with a tyrosine for future radioiodination or
spin-labeling with a nitroxide moiety. Again, because we
were interested in antigen processing and presentation, Ii-3
was not end-blocked.
CD spectra of Ii 3 peptide. As shown by Table 3. 5, Ii-3
did not coil as an a-helix in 10 ro phosphate buffer, but it
formed 51% and 18% helicity in 45% TFE and lipid vesicles,
respectively Fig. shows the of thesespectra
experiments including the control CD spectrum with lipid
vesicles alone.
3 binds to purified class II MHC molecules. The
general plan of this experiment was shown in Fig. 4.
using a technique similar to that of Buus et al. (1986b) ,
sufficient quantities of class II MHC molecules were purified
their Ii-3. Several importantbindingassess
modifications were made to ensure a high quality binding
result.
E -2.
102
200 220 240
Wavelength (nm)
Fig. CD spectra of 1i.3 in 10 mM phosphate buffer (B), in that
buffer with 45% TFE (T) and with lipid vesicles (V) at room temperature.
The unmarked spectrum in the lower panel shows lipid vesicles alone.
cell lysis an detergent I
solubilizatin t
Solubilized Membrane Proteins
l243 mAb Affinity Column
Purifed Class II MHC
(Ii dissoiated)
103
11-3 Peptide
Coupling with HSAB
1i- HSAB 
kxna
(125
1)1i- HSAB
Incubated for 48 hr
PHOTOACTIVATION
CROSSLINKED COMPLEXES
GEL ELECTROPHORESIS
F1g. 4.5 Exper1mental steps of 11-3 b1ndlng to affin1ty pur1f1ed class II
MHC molecules from Jesthom cells.
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First, anti-DR mA L243 was selected because it could
immunoprecipitat class II MHC molecules free of associated
invariant chains. It was suggested by Shackelford et al.
(1981) that L243 antibody could recognize a DR epitope that
became exposed these molecules matured. Immuno-
precipitation of Rajl cells with L243 antibody showed clear a
and p chains of class II MHC with very little Ii (unpublished
data) . Before using L243, other anti-DR antibodies were
tested in this type of experiment, but without success. One
problem was that those antibodies could only precipitate the
class II MHC/Ii complex which did not bind Ii-3 unless some
mechanism could be found to deplete the Ii molecules from the
complex.
Another major modification on the purification of class
I I MHC molecules was that antibody orientation kit 
(P ierce) was used to make the immunoaff ini ty column.
conventional techniques, antibodies were randomly immobilized
to activated beads with multiple-site attachment and possible
misorientation the immunoglobulin molecules, which
reduced the efficiency of the Ab/Ag reaction. With the
orientation kit which uses protein A-agarose, the Fc portion
of the antibody molecules first bound to Protein A, allowing
the antigen binding sites to be pointed outwards, and then
the antibodies were crosslinked to immobilized Protein 
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The immunoaffinity column thus made with L243 mA could have
a higher binding efficiency to purify class II MHC molecules.
These methods produced a good purification of class II
MHC molecules. After running L243-affinity column-purified
materials in SDS-PAGE, the Coomassie blue staining of the gel
showed a large amount of purified and p chains of class II
MHC without detectable Ii molecules (Fig. 4. 6).
The photoactivatable and heterobifunctional cross linker
N- hydroxy s ucc in imidy 1- 4 -a z idobe n zoa t (HSAB) was used.
was first coupled to Ii-3 at pH 7. 4 in the dark, followed by
iodination of the peptide. The iodinated Ii-3-HSAB, which
was separated from free 125I in a P-6 DG (Bio-Rad) gel
filtration column, was incubated with affinity-purified class
II MHC for 48 hr at room temperature. At the end of the
incubation, the bound molecules were crosslinked by exposure
to short wavelength ultraviolet light for 30 min and the
complexes were subjected to SDS-PAGE and autoradiography.
Fig. 7 demonstrated clear binding of Ii-3 to both and p
chains of the class II MHC molecules. Cold Ii-3 peptides
could compete with such binding (Fig. 4. 7, lane 3) and several
copurified proteins beyond the alp complex range were not
bound by the peptide (Fig. 6 and 4. 7), suggesting that the
Ii-3 peptide binding to class II MHC molecules was specific.
The binding appeared to be saturable because addition of more
(125 I) 
-labelec:Ii-3 did not show significant increase of
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binding (Fig. 4. 7, lane 2) The nature of a higher molecular
weight band (-60 kD) was not clear, but it could be an alp
dimer of class II MHC molecules (see more in DISCUSSION) 
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Fig. 4.6 1-D SDS-PAGE analysis of unlabeled. affnity purified clas
II MHC molecules from Jesthom cells. The gel was stained by
Coomassie blue.
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Fig. 4.7 1-D SDS-PAGE and autoradiography analysis of affnity-purified
molecules from Jesthom cells (100 nM) crosslinked by 50 nM HSAB-
coupled, iodinated 1i-3 peptide with (lane 3) or without (lane 1) 5 J,M
noniodinated 1i-3, or 150 nM (lane 2) HSAB-coupled, iodinated 1i-3 peptide
alone.
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B. CS-li Synthesis in the Absence of Class II-MHC Molecules.
P3HR l does not e press class II MHC. Jijoye, and its
mutant, daughter cell line, P3HR-1, came from a Burkitt'
lymphoma patient (Hinuma et al., 1967). The lack of class I I
MHC proteins in P3HR-1 cells was shown by its failure to
immunoprecipitate class II MHC molecules with the anti-human
class II MHC antibodies anti-23, 30 and SG157 (Spiro et al.,
1985) . Therefore, P3HR-1 was selected to study whether CS-li
could synthesized absence class MHCthe
molecules.
First, the lack of class II MHC molecules in P3HR-1
cells was further confirmed with another anti-human class 
MHC mA IVA-12 which has a broad specificity against various
kinds of human HLA-D products. While the parent cell line
Jijoye clearly demonstrated the synthesis of class II MHC
molecules, immunoprecipi tat ion detergent- sol ubi lized,
(35s)methionine-labeled, P3HR-l microsomal membrane with IVA-
12 did not show any detectable expression of either or ~
chains class MHC (Fig. 8) . The expression
(35S) methionine-labeled Ii molecules in both cell lines
appeared to be at same level. Results from 2-D gel analysis
confirmed the identities of the bands shown by 1-D SDS-PAGE
(Fig. 9) . The strong band at -43 kD was actin and was used
f#.
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Fig. 4.8 SDS-PAGE and autoradiography analysis of immuno-
precipitated, (35S)methionine-labeled microsomal membrane proteins
from Jijoye and P3HR- cell lines.
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Fig. 4.9 2-D nonequilibrium pH gradient electrophoresis (NEPHGE) and
autoradiography analysis of immunoprecipitated. (35S)methionine-
labeled microsomal membrane proteins from Jijoye and P3HR-1 cell
lines.
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as the quantitative indicator for the relative synthesis of
Ii and class II MHC in both cell lines.
P3HR 1 could synthesize CS li. Following (35S) sulfate-
labeling and immunoprecipatation with anti-Ii mA VIC-Y1,
SDS-PAGE analysis sulfate-bearingdemonstrated that
component synthes i zed considerablewas P3HR-1 with
molecular weight heterogeneity (Fig. 4 . 10) . Such a pattern
was typical for CS-li as reported in other similar studies.
After treatment of the precipitates with chondroitinase-ABC
(CHase), the sulfate-bearing molecules from P3HR-1 cell line
disappeared, confirming that above molecules were CS-li.
This result provided direct evidence of the class II MHC-
independent synthesis of CS-li.
As a positive control, the Jijoye cell line synthesized
CS-li which was detected by both anti-class II MHC and anti-
Ii monoclonal antibodies, showing that in Jijoye cells at
least some CS-li was associated with class II MHC/Ii complex
(Fig. 10) . sulfate-labeled band around 35 kDA separate,
was present in immunoprecipitates from Jijoye but not from
P3HR-1, and it was not affected by CHase treatment. This
pattern was typical of the sulfated chain of class II MHC
molecule as reported by Sant et al. (1988) . Lack of this
molecule in P3HR-1 supported the view that there was no class
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II MHC synthesized in P3HR-1 and the higher molecular weight
smear found in P3HR-1 with anti-Ii mA was only CS-li.
Nevertheless, the CS-li found P3HR-1 cells had
several differences from that of Ji joye. More CS-li was
synthesized when the cells did not express class I I MHC
molecules. Also, the relative molecular weight range of CS-
Ii in p3HR-1 was somewhat higher than that of CS-li in Jijoye
cells, shifting from 45-66 kD to 50-90 kD (Fig. 4. 10) .
From the strong smear on SDS-PAGE gel, it was possible
to see several separable bands on the CS-li precipitated from
P3HR-1 cells. Since all of the previously reported CS-li
molecules were shown by 1-D gel as evenly spread smears,
current results might suggest that the CS- I i was formed
mainly as a few core species in the absence of class II MHC.
After processing of the autoradiographic film by computer
scanning, such species were identified as 53, 56, 60 and 
kD, respectively (Fig. 11).
The identity of CS-li from P3HR-1 cells was confirmed by
another approach. The anion-exchange resin DEAE-Sephacel
column was used to purify CS-li from P3HR-l in a fashion
similar that reported by Giacolet to al. (1986)
(Fig. 12) . The DEAE-Sephacel co 1 umn not only purified
(35S) sulfate-labeled also concentratedCS- Ii, but
(35S)methionine-labeled CS-li which was not detectable by
direct ant i-oZi mAb precipitation, only small
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Fig. 4.10 SDS-PAGE and autoradiography analysis 
immunoprecipitated. (35S)sulfate-labeled microsomal membrane
proteins from Jijoye and P3HR-1 cell lines. Some samples (+) were
treated with chondroitinase ABC (CHase) at a concentration of 2 U/ml.
Others were mock-treated (-).
g66
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Fig. 4.11 The lane shown in Fig.4. 10 as immunoprecipitated by VIC- Y1
and untreated with CHase was further processed by a Epson Equity 11+
computer system with the scanning software Image Measure
(Microscience, Inc., Federal Way, WA) to expose the core proteins. The
picture shown here was taken from the computer monitor screen.
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Fig. 4.12 SDS-PAGE and autoradiography analysis 
(35S)methionine labeled (lanes 2, 3, 4, 6, 7, 8, 10, 11, 12) or
(35S) sulfate labeled (lanes 1, 5, 9) microsomal membrane proteins
from Jijoye and P3HR-1 cells. The radiolabeled cell lysates were
applied to the anion-exchange resin DEA-Sephacel (Pharmcia), which
was well washed before the bound materials were eluted with a high
salt solution. Lanes 1-4 are direct imunoprecipitations from cell
lysates before added to the resin. Lanes 5-8 are imunoprecipitates
of the pooled resin wash. Lanes 9-12 are imunoprecipitates of
eluted bound materials. Anti-Ii mA VIC-Y1 (lanes 1, 4, 5, 8, 
12), and anti-class II MHC mA IVA-12 (lanes 2, 6, 10) and anti-class
I MHC mA W6/32 (lanes 3, 7, 11) were used.
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percentage of Ii formed CS-li. The core protein of this
DEAE-Sephacel eluate was shown to be Ii because only anti-Ii,
but not anti-class I or anti-class II MHC antibodies, could
immunoprecipitate materials contained in the column eluate.
Cellular localization of Ii in Jijoye and P3HR-1. Since
the above results showed that CS-li could be synthesized 
the absence class MHC but with structuralsome
variation, the cellular localization pattern of Ii in P3HR-1
cells was further examined by indirect immunofluorescent
microscopy analysis. For both Jijoye and P3HR-1 cells, most
of the intracellular Ii molecules detected with anti-Ii 
VIC-Y1 were localized at the Golgi complex region (Fig. 4. 13,
14). Anti-chondroitin sulfate mA (7D4) stainings of both
cells were not strongly positive (Fig. 4 . 15, panel C and D).
This result might be due partially to the limited amount of
CS-li in each cell. Anti-class I I MHC mA (IVA-12) did not
stain P3HR-1 cells (Fig. 15, panel B). Therefore, no major
difference in Ii distribution patterns between these two cell
lines was observed by this technique.
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Fig. 13 Immunofluorescent staining of Jijoye cells with VIC-Y1 (A)
and wheat germ agglutinin (WGA) (B).
" ,
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Fig. 14 Immunofluorescent staining of P3HR-1 cells with VIC-
(A) and WGA (B).
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Fig. 15 Immunofluorescent staining of Jijoye (A, C) and P3HR- 1 (B , 0)
with IVA-12 (A, B) and 704 (C, 0).
IV'
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C. Ii Is Dissociated from Class II MHC by
Proteolytic Cleavage
Proteolyt ic cle ava cathepsin B . It was
generally accepted that Ii was cotransported with class 
MHC through several cellular compartments until later
dissociated from class II MHC in an endosomal compartment.
Such a dissociation step was critical because it would allow
processed antigenic peptides to bind to the desetope of class
II MHC molecules. It was suggested that the dissociation of
Ii might be the result of protease cleavage, but there was no
direct evidence to show which protease could play this role
and whether the protease could selectively cleave Ii but not
the closely associated class II MHC molecules.
While addressing this question, we have demonstrated
that cathepsin B and cathepsin D could be the candidate
proteases for this process (Reyes et al., 1990) . With 
vitro treatment of the lysate of B lymphoblastoid cell line
Jesthom with cathepsin it was found that Ii could be
cleaved and released from class II MHC molecules at pH 5.
without apparent damage to the 
and p chains of class II MHC
(Fig. 4. 16). Ii was cleaved in a dose dependent fashion with
the complete removal of Ii at 5 U/ml cathepsin B. Leupept in
could block the activity of cathepsin B and restored the
pattern of Ii molecules seen in the absence of cathepsin B
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(Fig. 17) . Complete protection from cleavage was achieved
with 10 leupeptin.
Cathepsin B cleavage generated a series of
intermediate and low molecular weight fragments shown by SDS-
PAGE (Fig. 4. 16 and unpublished data) . Some could match with
the in vivo Ii cleavage products, such as p21 molecule, while
some were only found in vitro cathepsin B treatment. It is
not known yet how these fragments were generated.
Production of anti Ii peptide sera In order to study
the cleavage of Ii in more detail, three polyclonal rabbit
anti-Ii petide sera were generated.
Two were produced by immunizing the rabbits with two 
peptides within the hypothesized long helix region, Ii-2 (146-
169) and Ii-3 (148-164) (Fig. 1), respectively. After several
immunizations, anti-li-2 was able to precipitate a pIS
molecule (Fig. 4 . 18) which was only present Ii-positive
cells (Fig. 19). Purification of this molecule for protein
sequencing analysis was attempted, but I did not succeed to
have enough for such a study.
Anti-li-3 could precipitate following denaturation a
molecule with the molecular weight range similar to the p31-
form of denaturing(Fig. 20) . the absence
conditions, a p41 molecule was precipitated from some mutant
Raji cells. This p41 molecule could overlap with the region
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of highly processed p41-form Ii in 2-D gels (Fig. 4. 21), but
peptide mapping supportiveeffort failed rea ch
conclusion. (Fig. 22) and ELISAHowever, the dot blot
(Fig. 4. 23) studies did suggest that anti-li-3 was a specific
antibody against the original Ii-3 peptide.
The third anti-peptide serum was raised against Ii-4 (78-
92 ) which had a palindromic sequence with six positively
charged residues (+) and four prolines (p) mixed with other
residues (0): + 0 + 0 P + P P + P 0 0 + 0 + (Table 3. 3).
This short sequence was located within the extracellular
region of Ii immediately next to its transmembrane portion.
Excepting for this region, almost all the other regions of
the Ii sequence had been tested for raising anti-peptide
serum by various labs. We felt that this anti-li-4 antibody
would useful identify cleavagethesome
fragments. An ELISA study of this serum showed that it was
specific for its peptide antigen (Fig. 4. 24) .
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Fig. 4.16 Cathepsin B cleavage and release of Ii from class II
MHC/li complex. Solubilized microsomal membranes from
(35S)methionine-labeled Jesthom cell line were treated with cathepsin
B (CB) at various concentrations and then immunoprecipitated with the
anti-class II mAb IVA-12. (Courtesy of Dr. V.E. Reyes.
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Fig. 4.17 Inhibition by leupeptin of cathepsin B-induced cleavage and
release of Ii from class II MHC molecules. Microsomal membrane
preparations were each treated with: none (A); cathepsin B at 5U/ml alone
(B); cathepsin B at 5U/ml plus leupeptin at 0. M (C), at M (D), at 1 0 
(E) and at 1 00 M (F). The samples were then immunoprecipitated with IV 
12 mA. (Courtesy of Dr. V.E. Reyes.
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Fig. 18 Immunoprecipitation of (35S)methionine-labeled Raji cell
membrane proteins with prebleed, bleed 1 , 2, 3, 4, and 5 from 1i-2
immunized rabbit (lanes 1 , 2, 3, 4 , 5, and 6, respectively). An anti-Ii antibo
E1 was used as control (lane 7). (Courtesy of M-Z. Xu).
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Fig. 4.19 Immunoprecipitation of (35S)methionine labeled Raji (lanes 1, 2),
Jesthom (lanes 3, 4), Vavy (lane 5, 6) and CEM (lanes 7, 8) cell membrane
proteins with anti- Ii-2 (lanes 2, 4 , 6, 8) and and anti-Ii antibody E1 (lanes 1,
7).
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Fig.4.20 Immunoprecipitation of (35S)methionine labeled Raji cell
membrane proteins with anti- Ii-3 (lane 2, 4) and pre bleed (lane 1, 3) in
native (N) and denatured (D) conditions.
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Fig. 4.21 2-D NEPHGE analysis of a p41 molecule immunoprecipitated
from (35S)methionine labeled Raji cell membrane proteins by anti-Ii-3.
130
Ii 148-164 A C D
10,.9
peptide
40,.9'
5fJ9 P336-35640,.9
Fig. 4.22 Dot blot analysis of anti- Ii-3 with serial dilution, 1 :40, 1 :160,
1 :640 and 1 :2560 (lane A, B, C and D, respectively).
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1i-3 as Ag
prebleed
Irrelevant Ag
No peptide
1/8 1/16 1/32 1/64 1/128 1/256 1/512 1/1024
Ab dilutions
Fig. 4. ELISA analysis of anti- li-
II 0.
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1/8 1/16 1/32 1/64 1/128
Ab dilutions
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1i-4 as Ag
prebleed
Irrelevant Ag
No peptide
1/256 1/512 1/1024
Fig. 4. ELISA analysis of anti- li-
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CHAPTER V
DISCUSSION
There central question thethe workone
previous chapters: why are only some peptides in antigenic
proteins selected for recognition by T cells? The pr imary
objective in my thesis research search for thewas
prototypic structure of T cell-presented peptides. The
theoretical and experimental studies with one model, PH-1.
supported the hypothesis that recurrent hydrophobic residues
peptides digested from a foreign antigen mightsome
stabilize helical coiling of those peptides by forming a
longit udinal, hydrophobic str ip against hydrophobic
surface. Such coiling could lead protection from
proteolysis and/or to scavenging and transfer of peptides to
a MHC desetope. The finding of this biophysical principle
leads to ideas about engineering of peptide vaccines and
provides information about protein folding in general.
Oriqin of the SOHHI. In an examination of the Hopp-
Woods (Hopp & Woods, 1981) hydrophilicity plot of Ii, a six-
cycle (Ii146-169) oscillation in hydrophobicity was found 
the frequency of an a-helix. Such unusual pattern
suggested that this segment might be important to maintain
the general structure of Ii or even played the role of
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binding to the antigen-binding site of class II MHC molecules
(Elliott, 1987a, 1987b) . If Ii146-169, in fact, binds class
II MHC molecules to cover the desetope, could one design an
algorithm based on its general structure to further predict
other T cell-presented peptides?
This idea was upported by the findings of Kaiser and
his co-workers. They proposed that some biologically active
peptides, hormones, assumed amphiphilic secondary
g. ,
struct ures in the presence of lipid membranes (Kaiser 
Kezdy, 1984) . When analogs were made with minimal specific
sequence homologies but with similar secondary structures,
they mimicked the membrane binding properties the
naturally occurring peptides. Analogs designed to optimize
the predicted secondary structures could even induce stronger
interactions than did the naturally occurring peptides.
appeared that the number of functional groups interact ing
with the hormone receptor was small and most of the amino
ac ids in this type of peptide served a purely structural
role, namely, the proper positioning of the ligand functions.
T cell antigens in many aspects were similar to peptide
hormones. They were all short to intermediate-size peptides;
they usually lacked disulfide bonds, they were linear in a
sense that the functional domains were not formed by distal
residues (Kaiser & Kezdy, 1984). Large foreign antigens were
processed to expose the buried T cell epitopes, while quite a
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few prohormones became activated proteolyticonly after
cleavage. Therefore, all these T cell-presented and hormone
peptides faced a similar question, i. e., how to refold the
shortened peptide either furtherescapesequence
degradation or to assume a conformation to play very specific
functions. The conformation of these short peptides depended
entirely on their environment. They could assume completely
different secondary struct ures detergentwater,
micelle, or in trifluoroethanol or other organic solvents
(Kaiser & Kezdy, 1984) . Since hormone receptors and MHC
molecules both membrane- integrated proteins, thewere
preference of peptide for amphiphilic secondaryhormones
struct ure implied that there might be also generalsome
structure patterns for T cell recognized antigens.
Sensitivity and efficiency of SOHHA. When the computer
program SOHHA was used to select T cell-presented peptides
and the selections compared with cellknownwere
determinants, it was found that the predicted sequences in
most cases did not overlap completely with the sequences
determined experimentally. This also happened when other
predictive methods were used (Table 3. 1). Two measures of
proximity, overlapping and touching, developedwere
evaluate the sensitivity and efficiency of the predictive
methods.
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It was difficult for a method to be both sensitive and
efficient, but SOHHA was clearly more sensitive and efficient
(0. 47 and 0. 35) than other methods in the more stringent
level overlapping (Table 2) . structureThus, the
predicted by SOHHA was presumably closer to the core sequence
of T cell-presented peptides. The amphipathicity and motifs-
4 methods could find a much higher fraction (0. 71 and 0.
respectively) of known T cell-presented peptides at a less
stringent level " touching , indicating that these two methods
actually predicted regions closely flanking the core sequence
of T cell-presented peptides. However, these two methods
achieved higher sensitivity losingthe expense
efficiency, e. , more T cell determinants were predicted by
making more predict ions. The overall low efficiency of all
three predictive methods listed in Table 3. 2 might reflect
our limited knowledge of known T cell determinants. It was
poss ible which predicted withthat some sequences were
algorithms but not experimentally reported, would be found to
be T cell-presented if additional mouse strains were tested
over a range of antigen concentrations.
Role of recurrent hydrophobic All threeresidues.
predictive methods depended, in varying degrees, on recurrent
hydrophobicity . For the SOHHA, recurrentthe measure of
hydrophobicity was the mean hydrophobicity of amino acids,
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falling in a longitudinal, hydrophobic strip of an a-helix.
SOHHA could also be adapted to examine 310 helix and pleated
sheets (Reyes et al., 1988) , but a-helix was used more
frequently as a model system. The amphipathicity algorithm
depended in part upon recurrent hydrophobicity but it weighed
equally all amino acids of the sequence. Consequently, very
hydrophilic amino acids were as influential in the score as
highly hydrophobic residues and hence a sequence with only a
high SOHHI might not be selected. Likewise, we considered
the motifs method to reflect alternating hydrophobicity, as
each motif was centered on two or three hydrophobic residues
and had hydrophilic boundaries. Frequently, two or more
motifs were found within a range of 10 to 20 residues (Table
1 ) and if the sequence were coiled as an a-helix, the
motifs would be placed at intervals that would display their
hydrophobic residues on the same longitudinal surface.
Therefore, speculated that the positioning
hydrophobic residues might be important in the selection of T
cell-presented peptides. This view was supported by the
hypothesized refolding process of newly digested antigenic
peptides (F ig. 6) , i. e 
. ,
recurrent hydrophobic residues
stabilized the growing secondary structure through their
interactions with a hydrophobic surface. The biological
membranes represented characteristic, anisotropic
environment due to the amphiphilic nature of the dividing
138
line between the aqueous solution and the lipid bilayer 
the membranes. It was then possible that this environment
could impose a secondary structure on the peptide. The free
energy contribution of locating the amino acid residues in
their optimal microenvironment was considerable and yielded
additional stability. Secondary structures which would only
have marginal or no stability in an aqueous solution could
very well become stabilized once located in the membrane.
If the above hypothesis were true, the selection of T
cell-presented peptides should be linked closely to the
forming of secondary structures. There are at least two
possibilities to explain the biological significance of this
process. First, it is possible that peptides with certain
secondary structures might be less susceptible to proteolytic
degradation and therefore might escape complete destruction
during antigen processing. A second explanation is that the
peptides thus preserved as membrane-bound structures would
have a better chance to bind to MHC molecules (Roof et al.,
1990) , either through higher local peptide concentrations
which overcome the low binding affinity (Babbit et al., 1985;
Buus et al., 198 6b) or by specific conformation of the
peptides. This idea is consistent with the observation that
lipase could strip antigen from the surface of the antigen
presenting cells and inhibited presentation of that antigen,
without interfering with the general function of the cells 
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measured the ability subsequent ly otherpresent
antigens (Falo et al., 1986, 1987).
Nevertheless, the study of peptide folding is a new area
with very limited information since the rational design and
construction of biologically active peptides becomes
attainable goal through the applications of the tools of
modern chemistry, e. g., the technique of solid phase peptide
synthes is. decided oursel ves how much thetest
recurrent hydrophobic residues could contribute the
formation of a secondary structure of peptides, especially in
a membrane-like structure.
Pept ides completely different secondaryassume
structures in different environments. We first tested the
secondary structures of a group of HPLC-purified peptides in
10 ro phosphate buffer, that buffer with 45% TFE and that
buffer with lipid vesicles of DHPC. The peptides varied
greatly in their proline and glycine content,sequence,
values of mean hydrophilicity and the SOHHI (Table 3.
4) . Since this group of peptides included both T cell-
presented peptides and non-T cell-presented peptides, their
CD spectra represented very different structures. It also
suggested that circular dichroism could be used in our
studies to measure the helicity of peptides.
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Short peptides 20 amino acids) were predicted by a
classical view not to show observable helix formation
aqueous solution and truly there were only a few examples of
such peptides, naturally occurring or of de novo design,
which have shown stable a-helical aqueousstructure
solutions. With some peptides, this was achieved by end-
blocking to avoid the helix-destabilizing interactions with
the helix dipole al. , 1985 ; Marquesee( Shoemaker
Baldwin, 1987). Since our interest was in antigen processing
and presentation, none of our peptides end-blocked.was
Therefore, it was not surprising to find that none of the
peptides analysis detectable helicalour formed
structure in 10 ro phosphate buffer alone (Table 3. 5).
In 45% 5 peptides within the group formed TFE,
helices. The dielectric constant of TFE is about one-third
that of water, 26. 67 vs. 78. 54 , respectively, at 25 (Nelson
& Kallenbach, 1986) . Even though the exact biophysical
nature of TFE I S role to stabilize a-helical structures is not
clear, suggested that (a) the stabilitywas
intrapeptide hydrogen bonds in TFE solution will be increased
in comparison with peptides in aqueous solution; (b) the
interactions between charged species would be stronger in TFE
solution and such interactions might be responsible for
stabilization of a-helix structures (Nelson & Kallenbach,
1986) . Lark et al. (1989) also reported that two T cell
ii/'
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antigenic peptides from sperm whale myoglobin, SWM 132-146
and SWM 102-118, folded as a-helical structure in 50% TFE as
shown by CD analysis while in aqueous buffer little ordered
secondary structure was found. In our study, Ii-4, MA-2 and
MA-3 could not form helical structures in 45% TFE, probably
as a result of 2 to 4 prolines in the middle of their short
sequences (Table 3. 3). MT11-A could not form an a-helix in
45% TFE, but it was the only peptide doing so among 6 in this
group without multiple prolines (Table 3. 3 and 3. 5). It had
the lowest SOHHI among these six peptides, but since MT11-A
was the only example in this group it was difficult to
conclude whether its low helix-forming tendency in TFE was
related to low SOHHI.
One major problem of using TFE to measure the helix-
forming tendency of peptides was its strong helix-promoting
effect which marginally stable pept ides formmade many
helices. Also, there was no stable and compatible standard
to judge the ability of a peptide to form a helical structure
in TFE because the higher concentration of TFE usually led to
a higher percentage of helicity for a peptide which could
form helical structure.
It appears that such a shortcoming of TFE was overcome
through the lipid vesicles experiments. In the presence of
well-sonicated lipid vesicles, a helix-forming tendency was
conserved for most peptides which had helical structure in
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TFE, but their percentage helicities were lower in lipid
vesicles (Table 3. 5). The predominant form of secondary,
structure for MX in the presence of lipid vesicles was 
pleated sheet in contrast to a-helix in 45% TFE. Thus lipid
vesicles stringent inducers pept idewere more
secondary When the helicitystructure. percentage
peptides in lipid vesicles, excluding those with multiple
prolines, against gene ra 1the SOHHI,plottedwere
correlation was found (r = 0. 77; P = 0. 07), suggesting that
the helix-forming tendency of peptides in lipid vesicles
depended more on their SOHHI. the sample size wasHowever,
too to small to draw a final conclusion.
Prototypic helix peptide. PH 1. o PH-1. 0, as a putative
mode 1, buil t axialwith components,two corewas
hydrophobic strip with a high SOHHI and a potential salt
br idge based on findings about peptide folding inrecent
aqueous solutions (Shoemaker et al. 1987; Marqusee & Baldwin,
1987; Marqusee et al., 1989).
By CD measurements PH-1. 0 did not show helical structure
in 10 ro phosphate buffer (Fig. 3. 7), but in lipid vesicles it
formed the highest helicity, room36%percentage
temperature and 40% at C, among all the peptides we have
tested (Table 3. 5, 3. 7, 3. 10, 3. 11). The mean hydrophilicity
of PH-l. O showed that it was not very hydrophobic in general
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and certainly very much less hydrophobic than several other
peptides tested. It appears that we generated a peptide that
was water soluble at physiological pH (data not shown) and
would partition into membrane in a controlled manner. The
result that PH-1. 0 had a superior helix-forming tendency in
lipid vesicles highly supported our hypothesis that the
recurrence of hydrophobic amino acids, in a polypeptide at
posi tions falling in an axial, hydrophobic strip if the
sequence were coiled as an a-helix, could lead to helical
nucleation on a hydrophobic surface. CD analysis of MT11-A,
which had very similar structural features as PH-1. 0 and it
had a low SOHHI, showed no helix formation and thus supported
our hypothesis (Fig. 3. 7-3. 9).
When the helix-forming tendency of PH-1. lipid
vesicles was examined various experimental
temperatures, it became clear that as the temperature was
increased, a structural transition from a-helix to random-
coil was taking place. When temperature was raised to 50
no clear helicity by CD measurement remained (Fig. 12). The
CD spect rum of PH-1. 0 in lipid ves icles at 75 C was very
close to the spectrum at 50 C (not shown). Since the phase
transition temperature of the lipid (Tt) was about 30 C, this
result probably reflected organizational changes of the lipid
vesicles which thus lost their ability to induce helix
formation of PH-1. a at temperatures above Tt.
tV'
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A clean isodichroic point at 202 nm was formed by the
various CD spectra from different temperatures (Fig. 3. 12),
indicating that the transition was two-state, e., each
amino acid was in either a helical state or a random coil
state. This finding did not imply that the formation of the
entire a-helix was two-state, or that the entire peptide was
either completely a-helix random coil (Nelson or a
Kallenbach, 1986) . Based on this explanat ion and if 
assume that every PH-1. 0 peptide formed the same degree of
helicity, the above result demonstrated that the transition
between random-coil and helix was a stepwise process in which
the recurrent hydrophobic residues played an important role
in anchoring the successive loops of a growing helix to the
lipid vesicles. Since CD analysis could not discriminate
whether 50% the peptide molecules formed 100% helicities
100% the peptides formed 50% helicities, the exact
nature PH-1. folding must determined from other
experiments, such as NM study.
The experimental results also excluded the possibility
that PH-1. 0 formed helical structure through the aggregation
of their strong hydrophobic residues. In 10 ro phosphate
buffer alone, for PH-1. did shownotspect ra
observable helical (Fig. When PH-1. 0 wasstructure 7) .
tested at a high peptide and salt concentration, there was
still no obvious helical shown by thestructure
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measurement (Fig. 3. 10). This suggested that PH-1. 0 would
not aggregate in aqueous solution, at least not before a
helical structure could be stabilized. Therefore, the strong
helix-forming tendency of PH-1. 0 could not be explained by
self-aggregation.
There was additional evidence that the formation of
helical structure of PH-1. in lipid vesicles was lipid-
dependent. First, ipid vesicles only formed after
sonication of the lipid solution, as judged by the formation
of an optically translucent suspension, and our experience
clearly suggested that PH-1. 0 would not be induced to show a
helical CD spectrum before lipid vesicle structure was formed
by proper sonication. Once the sonication was successful,
the secondary structure pattern and the percentage helicity
of PH-1. 0 in various lipid vesicles experiments were always
very similar. Without the presence lipid vesicles,
sonicating PH-1. 0 in aqueous solution did not induce helical
structure. Second, optimal lipid/peptide ratio was
required for PH-1. 0 to form a helical structure (CD spect ra
not shown). In most of our lipid vesicles experiments, the
optimal
basis.
ratio of lipid to peptides was -50/1 on a molar
PH-1. 0 would not form a-helix with less lipid, but
more lipid than the optimal range did not further increase
the percentage helicity. This again demonstrated that the
helix-like CD spectra in lipid vesicles experiments truly
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represented the structure of the peptide rather than the
interference of lipid vesicles.
An ESR study of the interaction between PH-l. O and lipid
ves icles further showed that the formation helical
structure was related to the direct binding of peptide into
lipid vesicles (unpublished observation) . will
poss ible to achieve detailed information about themore
orientation of PH-1. 0 in lipid vesicles if additional peptide
analogs are made with the tyrosine residue placed in various
positions.
As expected, PH-1. 0 formed an a-helix in TFE solution
(Fig. with a high percentage helicity, -60% a t room11 )
temperature and 76% at 40C (Table 3. 5, and 3. 7). The higher
the concentration of TFE, the higher the percentage helicity
was induced (Table 3. 6). Since we only tried 30-45% TFE 
these experiments, it might be possible to induce higher
percentage helicity with more TFE 
Numbe r and placement hydrophobic residues
longitudinal strip governs helix formation of peptides in the
presence of lipid vesicles. As discussed previously, two
core components, the longitudinal, hydrophobic strip and the
potential salt bridge (including the orientation of its
charged residues), were considered to stabilize the helical
structure of PH-1. We designed a large number of analogs
';;.' " ,
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for PH-1. 0 to study the contribution of each of these two
components (Fig. 3. 13-3. 15).
The simplest way to analyze the importance of recurrent
hydrophobic residues in PH-1. 0 was to replace them with much
less hydrophobic residues, threonine. Thesuch
substitution could be made with one residue only, or several
a t the time with various combinations at differentsame
positions along the longitudinal, hydrophobic strip (F ig .
13) . Another examine importance theway the
recurrent pattern of hydrophobic residues was to alternate
the leucine residues in PH-1. 0 to other locations than the
hypothetical hydrophobic strip to see if the helix-forming
tendency of this peptide was decreased (Fig. 3. 15 . A) .
In order to study the contribution of charged residues
in PH-1. 0, the potential salt bridge Glu4_Lys 7 could be broken
by (a) replacing one of these two residues with non-charged
residue (PH- 2 . 1-2. 3) or with the residue of opposite charge
(PH-2. 5-2. 6) , and (b) placing these two residues at such a
distance that they would not be close to each other when the
peptide coils as an a-helix (PH-2. 4) (Fig. 3. 14). The effect
of charged residues on the macrodipole of an a-helix could be
studied with similar logic (Fig. 3. 14).
Eight analogs of PH-1. 0 were synthesized with varied
number and position of leucine residues in the longitudinal
hydrophobic strip (PH-1. 1 to 1. 7, 1. 10). While none of these
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eight analogs, like PH-1. 0, formed a-helix in 10 ro phosphate
buffer alone (Fig. 17), some of them formed distinctive
helical structure in the presence of lipid vesicles at 40C
(Fig. 3. 19). Careful examination of these CD spectra led to
the following findings: (a) substituting even one of the
leucine residues in the longitudinal strip with threonine,
independent the location, led the reduction
peptides ' helix-forming tendency in lipid vesicles; (b) s
an effect was more damaging when the substitutions were made
in the middle of this strip (PH-1. 2 and 1. 3); ( c) when
several substitutions were made simultaneously, maintaining
at least two leucine residues in the middle of the strip was
necessary to form a helical structure (Ph-1. 7) ; (d) the
leucine res idues two ends the strip contributed
differently in the induction of helical structure in lipid
vesicles, i. e., PH-1. 4, with N-terminal leucine, had a higher
percentage helicity than the C-end leucine preserving PH-1.
(Fig. 3. 19, Table 3. 10), suggesting an orientation preference
of peptides in interacting with lipid vesicles.
conclude that preserving two strong hydrophobic
residues in the middle of a longitudinal hydrophobic strip
for a 13-residue peptide like PH-1. 0 is critical to induction
an a-helix in lipid vesicles. Such a sequence-dependent
pattern was unique to lipid vesicles because all of these
eight analogs demonstrated very typical, helix-like
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spectra with close percentage helicities when they were
examined in 45% TFE solution (Fig. 3. 17, Table 3. 8).
Again, the helix-forming tendency of analog peptides was
temperature dependent. PH-1. 1 maintained 26% helicity even
at 75 C in 30% TFE, (Fig. 3. 18, Table 3. 9), while in lipid
vesicles, CD spectra of these analogs did not show helical
structure when the temperature was raised to (Fig.
19). These and previous results about PH-1. 0 showing a
thermal transition consistent with other classicalwere
studies of peptide folding, e. g., C-peptide of ribonuclease
(Bierzynski et al., 1982; Shoemaker et al., 1987), indicating
that the helix formation of our prototypic helix peptide was
enthalpy-driven (Marqusee & Baldwin, 1987). It was suggested
that one candidate for the enthalpic contribution to helix
formation was the hydrophobic interact ion, which becomes
increasingly enthalpy-driven at higher temperatures (Baldwin,
1986; Marqusee & Baldwin, 1987) . In fact, the successful
examples of peptides folding to a-helices in many studies
were found at or close to OOC, pept idee. g.,
(Shoemaker et al., 1985) and at 5 (Shoemaker et al., 1987),
Ala-based pept ide de novo design at (Marqusee
Baldwin, 1987; Marqusee et al., 1989) and at OOC (Padmanabhan
et al., 1990). Recently Talanian et al. (1990) reported that
a sequence-specific DNA binding peptide, GCN4-br1, which
adopted a helical structure when bound to DNA, bound DNA
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better at C than at C as tested by deoxyribonuclease
(DNase) I footprinting analysis. Therefore, we hypothesized
that the percentage helix formation at the low temperature
shown by in vitro biophysical studies may represent the true
helix-forming tendency of that peptide ' vi vo, but there
might additional unknown factors stabilize such
structure at physiological temperatures.
The ninth analog of PH-l. 0 synthesized with awas
leucine at position 3 (Fig. 16) . Because Leu3 in this
analog, PH-4. 2, changed the recurrent hydrophobic pattern in
the N-terminal part of the peptide, we tried to test whether
hydrophobic residues in strips other than the hydrophobic one
in a potential a-helix could compete to break the helical
structure. The CD analysis showed that PH-4. 2, different
from other analogs, formed helical lipidst ruct ure
vesicles at both C and at room temperature (Fig. 3. 20).
However, the helix-forming tendency of PH-4. 2 was not 
strong as PH-1. 0, as judged by their percentage helicities
(Table 3. 11). Thus, addition of a hydrophobic residue at
position 3 while preserving the strong longitudinal strip and
other structural features could reduce, but not completely
inhibit, the coiling of this peptide into an a-helix. From
the current CD result, we could not tell whether PH-4. 2
actually formed other secondary structures, such as ~-pleated
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sheet to compete with the strong hydrophobic strip in the
presence of lipid vesicles.
Funct ional significance of the prototypic helix peptide.
The immunological relevance of PH-1. 0 in antigen presentation
was shown in one functional study in which PH-1. 0 could
inhibit the presentation of a DR 1-restricted peptide M1 17-
31 of M1 matrix protein of influenza A virus. PH-l . 0 had
very little primary sequence homology with M1 17-31 (Fig.
21) but its ability to inhibit the presentation of M1 17-31
was as good as another DR 1-restricted peptide, HA 307-318
(Fig. 23) . Since 17-31 cou ld formand
longitudinal, hydrophobic strip if the peptide coiled as an
a-helix (Fig. 21), the results supported our hypothesis
that the foreign antigenic peptides could be selected through
their potential hydrophobic strip of a helical structure and
it was highly possible that the prototypic helix peptide, PH-
0, competed with M1 17-31 as a result of its high SOHHI
value.
The above results, both biophysical and functional,
raised the question of whether a helical struct ure was
required for T cell-presented peptide. Statistical ( Spouge
et al., 1987 ; Margali t et al., 1987; Stille et al., 1987;
Reyes et al., 1988) and some functional (Schwartz et al.,
1985; Berkower et al., 1986; Cease et al., 1986; Carbone et
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al., 1987; Allen et al., 1987c) results indicated that an 
helical structure might be required for many T cell antigenic
peptides. The re were also functional studies arguing that
such a structure might not be an obligatory requirement for
some other T cell determinants (Heber-Katz et al. , 1985;
Sette al. , 1987; Ogasawara al. , 1989; Bhayani
Paterson, 1989). Most of the above conclusions were reached
by structural modeling of peptide sequences with very limited
experimental data from direct structural measurements, e. g.,
CD and 2D NMR. Peptide structures were proposed in some
studies based on the assignment of certain amino acids within
the peptide as MHC-contacting or TCR-contacting residues by
functional analysis of a series of analogs containing single
amino acid substitutions (Sette et al., 1987; Ogasawara et
al. , 1989), but was impossible to be sure that any
particular amino acid substitution only influenced direct
contact with MHC or TCR and did not affect the general
struct ure the peptides. was possible that some
secondary struct ures,
g. ,
an a-helix, could maintain a
short peptide in a relatively stable conformation only when
placed in the right environment. Our results with PH-1. 0 and
its analogs were consistent with this view.
The hypothesis that there were relati vely common
structural features for immunogenic peptides was supported by
the concept of degenerate binding of peptides to class II MHC
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molecules (Roche & Cresswell, 1990) since there was neither a
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significant affinity difference nor a kinetic preference for
the association of an influenza hemagglutinin peptide, HAp,
with either DR1, DR5, or DR8 molecules. Grey and co-workers
(Buus et al., 1987; Sette et al., 1989) reported that when
data from a large panel of peptides were analyzed, a peptide
that bound individual I-A I-E allele had
significant probability of binding to other alleles of the
same locus. Sinigaglia al. (1988) found that
circumsporozoite protein-derived peptide was capable of being
recognized by T cells in association with many different
human and mouse class II MHC molecules. An influenza virus
matrix protein-derived peptide could bind to both DR1- and
DRw13-positive B cells (Ceppellini et al., 1989). Thus, even
though it was generally assumed that the specific association
of a given immunogenic peptide with a particular class II MHC
molecule was direct ly respons ible for the observed MHC-
restriction of T cells, these recent results did suggest that
the specific association of the TCR with the peptide-class II
MHC complex might be more important in determining the final
T cell response. Therefore, a clear pattern of recurrent
hydrophobic residues may only promote the association of
immunogenic peptide with MHC molecules but the peptide/MHC
complex expose different sets of residues to different T cell
clones (Bhayani & Paterson, 1989; Kurata & Berzofsky, 1990).
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Our results clearly showed that only a few critical,
recurrent hydrophobic residues might be enough to induce a
helical structure (e. g., PH-1. 7), thus various peptides could
form a similar secondary structure and at the same time still
maintain their fine specificity to induce very specific T
cell response. In addition, a change in the positioning of
hydrophobic residues (e. g., PH-4. 2) might generate more fine
specificities.
It is still not clear how an immunogenic peptide can be
fitted into the peptide-binding cleft on the class I MHC
molecules (Bjorkman al. , 1987) and the similar yet
hypothetical structure of the class II MHC molecules (Brown
et aI, 1988). Comparison of X-ray crystallography structures
of HLA-Aw68 and HLA-A2 found that side chains of peptide
antigens could interact with specificity pockets in the
peptide-binding cleft and one prominent pocket, a hydrophobic
cavity with Met 45 at its base (the n 4 5 pocket" remained
essentially conserved between these two alleles (Garrett et
al., 1989). Since the cleft was too small to hold the whole
length of many known T cell immunogenic peptides,
possible that only part those pept ides, core
sequence, could actually access the binding pockets (Sette et
al. , 1987) . Hence, residues outside the minimal
immunodominant site might play other roles, such as to
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maintain certain important conformations for T cell-presented
peptides.
least four explanations for the need of certain
conformations could suggested. First, stable
conformation might position the critical residues
pept ide proper orientation order induce the very
specific cell response. Many studies have suggested that
different T cell clones could recognize a single peptide
bound with the same MHC molecules differently (Bhayani 
Paterson, 1989; ' Kurata Berzofsky, 1990; Boyer et al.,
1990) .
Second, it was possible that structural features outside
the core antigenic determinant could influence the magnitude
of the T cell response, either increasing the potency of the
peptide (Schwartz et al., 1985) or exerting negative effects
on recognition by antigen-specific T cell clones (Vacchio et
al., 1989).
A third possibility, independent of binding to the MHC
molecule, but not mutually exclusive, was the ability of
those peptides with a-helical conformation, to intercalate
into membranes (Collawn et al., 1989, Collawn & Paterson,
1990) . Mecheri et al. (1990) have shown that immunogenic
peptides require an undisturbed phospholipid cell membrane
environment and must be amphipathic to immobilize class 
MHC molecules on B cells.
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fourth explanat ion for the importance some
structural features, especially for the helical structure,
was that such structure might less susceptible
proteolyt ic degradation and therefore might escape
destruction during processing. This hypothesis is currently
under active investigation in our lab.
Ii (148 164) forms an a helix in lipid vesicles and binds
to both cha s of class II MHC molecules. More than
three years ago, Elliott et al. (1987a, 1987b) hypothesized
that (a) a 24-residue segment in Ii sequence (Ii146-169) might
form an amphipathic, a-helical structure and (b) it would be
the sequence bind the class MHC molecules order
cover the ant igen binding site (desetope) until
dissociation endosomes where foreign pept ide would
bound to clas s I I MHC molecules. This blocking function of
has been supported more and more studies
intracellular traffic and processing of protein antigens,
especially by Long s hypothesis (1989) that the invariant
chain might be involved in the distinction between class I
and class II MHC molecules in presentation of endogenous
ant igens . Nevertheless, the hypothesis of Elliott et al. was
directly confirmed by the biophysical and biochemical studies
of Ii-3 presented in this work.
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CD measurement of the secondary structure of Ii-3, a 17-
residue (148-164) peptide from the proposed a-helical region,
clearly demonstrated that it formed 51% helicity in 45% TFE
solution and 18% helicity in lipid vesicles (Fig. 4. 4, Table
5) . From the st udies of PH-1. 0 and its analogs,
appeared that the recurrent hydrophobic residues in Ii-3
might promote the nucleation the helix because the
hydrophobic residues in this short peptide only fell within a
longitudinal strip when the peptide coiled as an a-helix
(Fig. 4. 1).
The subsequent crosslinking experiment of Ii-3 provided
direct evidence that Ii-3 was capable of binding both and p
chains of immunopurified class II MHC molecules (Fig. 4. 7).
This was consistent with a report that T cell-presented
peptides could bind to both and ~ chains of class II MHC
(Buus et al., 1987) and was supported by the hypothesized
structure of pept ide-binding cleft on the class MHC
molecules (Brown et al, 1988) which was formed by both and
chains.
Teyton et al. (1990 ) recently showed by transfection
experiments that the invariant chain could independently bind
both and ~ chains of the class II MHC molecules, but they
did not know whether the invariant chain had two independent
sites for binding of the and ~ chains, or whether a single
site on Ii recognized similar structural features of the two
Ii.
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subunits of the class II MHC molecules. Our result that the
same Ii-3 peptide bound both 
and p chains of the class II
MHC molecules supported the second possibility.
There was an additional higher molecular weight band
(-60 kD) crosslinked by Ii-3 and shown by SDS-PAGE analysis
(F ig. 4. 7) . It was not clear about the nature of this band,
but similar findings in other studies suggested that it could
be the a/~ dimers (Buus al. , 198 6b; 1987 ; Roche
Cresswell, 1990b), because HLA-DR a/~ dimers were previously
shown remarkably stable dissociation SDS
(Springer et a 1. , 1977 ; Cresswell, 1977). The complete
dissociation of a/~ dimers might need boiling the sample at
1000C for 5 min (Roche & Cresswell, 1990b) or even 15 min
(Wraith et al., 1989), while our sample was only boiled 1 min
before electrophoresis. It was also postulated that this
unknown molecule found during peptide-class II MHC binding
might high molecular weight species (Roche
Cresswell, 1990a), but its nature has not been confirmed.
The fact that Ii-3 formed an a-helix in lipid vesicles
and bound class II MHC molecules was consistent with the view
that T cell-presented peptides have the potential to form
helical structures and further supported the hypothesis that
Ii' s function was to protect the desetope of class II MHC
molecules (Elliott et al. 1987a). This hypothesis was also
supported by recent studies which showed that invariant chain
*i'
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association with molecules inhibited immunogenicHLA-DR
pept ide binding (Roche Cresswell, 1990a) and that the
bindings of peptide and invariant chain to class II molecules
were mutually exclusive (Teyton et al., 1990).
However, our data did not imply that a helical structure
of Ii-3 must directly contact the desetope but rather 
might be needed for invariant chain to bind tightly to class
II MHC molecules and to prevent the binding of immunogenic
peptides. shown that the KD for the interact ionIt was
between the soluble Ii and affinity-purified HLA-DR molecules
was 5 X 10-8 to 3. 0 X 10- 9 (Teyton al. , 1990) ,
indicat ing much higher affinity than that most
immunogenic peptides, 2 X 10-6 M (Babbitt et al., 1985; Buus
et al., 1 98 6b) But if the class II MHC molecules were
highly purified without the association of Ii, the binding
affinity of immunogenic peptides was increased to 1. 3-2. 8 x
10-8 M (Roche & Cresswell, 1990b). Therefore, if Ii-3 really
represented the site on Ii to bind to class II MHC molecules,
a helical structure with a narrow, strong, hydrophobic strip
might contribute significantly to the above high binding
affinity of Ii. It would also make sense for immunogenic
peptides to assume a similar secondary structure in order to
support their core determinants to interact with the desetope
with a higher affinity, thus demonstrating a higher potency
in the induction of a T cell response. A competitive binding
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analysis between Ii-3 and immunogenic peptides would be able
show whether they bind same site clas s MHC
molecules. The binding site could be further identified by
mapping the crosslinked sequence on MHC molecules.
synthesis the absence class MHC
molecules. It was generally believed that Ii was associated
with class II MHC molecules throughout post-translational
processing (Jones et al., 1978) until their dissociation in
endosomal compartments. Some of the I i molecules could be
converted to a proteoglycan form (Sant et al., 1983, 1984,
1985a, 1985b; Giacoletto et al., 1986) . It was estimated
that only a fraction (2-5%) of the total cellular class 
MHC molecules contained CS-li (Sant et al., 1985b). It was
noted that CS-li might function in antigen processing and
presentation events (Sivak et al., 1987; Rosamond et al.,
1987), but the detailed mechanism was not known. It was not
known what was the role of class II MHC molecules during the
synthesis of CS-li.
Our study of the synthesis of CS-li in a class II MHC
negative cell line P3HR-1 clearly demonstrated that CS-li
could be synthesized in the absence of class II MHC molecules
(Fig. 10). This finding showed that intracellular
trafficking of the core proteins of CS-li did not need the
presence of class II MHC molecules and it was consistent with
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the report that CS-li might only be associated with class II
MHC molecules transiently (Sant et al., 1985b).
The synthesis of CS-li increased P 3HR-1was
comparison with Jijoye, its class II MHC-expressing, parent
cell line (F ig. 10), while at the same time it appeared
that Ii was terminally processed to more acidic, sialic acid-
derivatized forms only in Jijoye cells but not in P3HR-1
cells (Fig. Spiro 1985). This finding4 . 9) al. ,
suggested that the regular processing of Ii to Ip and the
synthesis of CS-li might represent two mutually exclusive
events regulated by class I I MHC molecules. In the presence
of class II MHC expression, most Ii was processed to Ip and
the synthesis of CS-li was only minimal, while in the absence
of class II MHC molecules, more I i was converted to CS- 
rather than moved through its regular processing pathway.
Such pathway selection for processing of Ii was consistent
with the report that addition of glycosaminoglycan (GAG) to
the core protein of CS-li happened in a cis-Golgi compartment
(Spiro et al., 1989a) . The resul ts of immunofluorescent
microscopy analys is suggested that the ma j 0 r i t Y
molecules in Jijoye and P3HR-1 cells were distributed within
Golgi complexes and there was no clear difference between
these two cell lines in their distribution patterns.
The average molecular weight of CS-li was greater in
P3HR-1 cells in the absence of class II MHC molecules than in
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Jijoye cells(Fig. CS-li4 . 10) . clear whywas not
synthesized in P3HR-1 had a larger molecular weight. Simonis
et al. (1989) also reported a CS-li molecular weight change
in the absence of class II MHC molecules, but that CS-li
appeared to be smaller, with a molecular range of 39-61 kD in
comparison to 43-80 kD found in the presence of class II MHC
molecules. While their result was based on a transfection
study with mouse cells, which could account for some of the
differences between the two studies, it was clear that the
presence or absence of class II MHC molecules certainly could
affect the GAG chain length of CS-li molecules (Simonis et
aI., 1989).
The multiple cleavage pathways for Ii molecules. The re
were least ma j 0 r proteolysis pathways. Onetwo
appeared to be responsible for the proteolysis of Ii to p25
which represented the C-terminal portion of and was
generated in an ER or cis-Golgi compartment (Thomas et al.,
1988) . Another pathway of Ii proteolysis has been described
(Blum Cresswell, 1988; al. , 1988) . TwoNguyen
proteolytic intermediates, p21 and p10, from a sialic acid-
deri vatized, complex sugar form of Ii were induced by the
thiol-protease inhibitor leupeptin. However, those fragments
were still associated with class II MHC molecules. It was
'\ )
163
not clear how Ii was actually released from class II MHC
molecules in an endosomal compartment.
The results presented in this work showed that cathepsin
B could completely cleave and release Ii from 
and p chains
of class II MHC molecules without apparent damage to those
cha ins (Fig. 16) . Such a cleavage could be blocked by
leupeptin (Fig. 4. 17). , Cathepsin B digested Ii in a dose
dependent fashion yielding multiple fragments, including a
p21 molecule (Fig. 4. 16). Since cathepsin B was found in
endocytic compartments where Ii appeared to be dissociated
from class MHC molecules (Guagliardi al., 1990) and
cell determinants produced from myog lobin cathepsin
digestion were presented cells without further
processing (Takahashi et al., 1989), it was highly possible
that for some antigens, a single protease, cathepsin B, might
be both necessary and sufficient for antigen processing and
Ii release. In this way, cathepsin B might work efficiently
catalyze the binding of immunogenic peptides to the
desetope of class II MHC molecules in order to overcome the
slow association rate for peptide charging of isolated class
II MHC molecules (Buus et al., 1986b).
Since cathepsin B at low doses generated p21 molecule 
vitro while leupeptin treatment of whole cells could only
block the further digestion of p21, it appears that p21 found
with leupept in treatment was the result incomplete
:.. :;,.
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inhibition of cathepsin B activity because a much higher
concentration of leupeptin to whole cells might be required
to achieve a similar effect as in our in vitro experiments.
Therefore, Ii could be released from class II MHC molecules
by one protease rather than by a previously proposed two-step
proteolysis mechanism (Blum &Cresswell, 1988).
Howeve r , important to make sure that the p21
generated in our cathepsin B experiment was same as the p21
molecule generated when the whole cells were treated with
leupept in . Towards this goal and to characterize the various
digested fragments during the proteolysis, several polyclonal
anti-Ii sera were produced by immunizing rabbits with various
synthesized Ii peptides coupled with KLH as carrier. Ant i-
Ii-2 precipitated a p18 molecule which might represent 
minor species leupeptin-induced fragments (Blum 
Cresswell, 1988) . Anti-li-3 and anti-li-4 was each specific
for their respect i ve ant igenic peptides in ELISA. They
should be useful in identifying respective Ii sequences in
proteolytic fragments and for additional experiments.
Overall, the structural and functional studies on PH-1.
and its analogs presented in this work showed that the
recurrent hydrophobic residues might play an important role
in the selection of T cell-presented peptides by formation of
1 - 
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helical structures, presumably in the endosomal vesicles.
PH-1 . 0 and its analogs shou Id tested further for
inhibition additional ant igens more antigen
presentation systems. Thus, the relationship between the
SOHHI of a peptide and its function of blocking antigen
presentation can be probed. New analogs, with other types of
hydrophobic residues falling in the longitudinal strip, will
provide more information about' the contribution of those
residues in the formation of an a-helix against a hydrophobic
surface. The study of peptides with alternately placed
hydrophobic residues, like those shown by Fig. 15, may
demonstrate how different types of secondary structures can
be induced based on the positioning of hydrophobic residues
and their interactions with a hydrophobic surface. Future
work in this area will certainly build the knowledge about
the structural requirements for T cell-presented antigens and
may facilitate the design of peptide vaccines.
The finding that Ii148-164 formed an a-helix lipid
vesicles and could bind class MHC molecules offered
another useful tool study, both structurally and
functionally, the interactions between cell-presented
antigens and class II MHC molecules. This peptide should be
tested in functional studies to see whether it can compete
with foreign, antigenic peptides. Biochemical character-
ization of crosslinked Ii-3/class II MHC complex may reveal
.. -\ i: ;,
I -
166
its actual binding site on class II MHC molecules. Further
modification of this peptide with knowledge achieved from PH-
1. 0 studies will useful further examinations
structural requirements for T cell-presented peptides.
The st udies CS-li and the proteolytic cleavage
pathways of Ii provided additional information regarding the
complicated process of post-translational modification of Ii.
It will help to understand finally the functions of this
molecule and the biochemical mechanisms controlling these
functions. Complete removal of the invariant chain from the
Ii/class II MHC complex also produced an experimental model
to directly test the mechanism of binding of various T cell-
presented peptides to Ii-depleted class II MHC molecules.
All of the above studies should allow us to understand better
the mechanisms that control antigen processing and
presentation immunogenic peptides ma j or
histocompatibility complex molecules.
, '
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